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ABSTRACT 
The 42kDa carboxyl-terminal processing fragment of Plasmodium falciparum 
Merozoite Surface Protein-1 (PfMSP-142) is one of the major anti-malarial vaccine 
candidate antigens. An expression system using recombinant Bombyx mori Nuclear 
Polyhedrosis Viruses (BmNPVs) carrying PfMSP-142 was established in our 
laboratory. Highly purified recombinant PfMSP-142 protein could be obtained by 
affinity chromatography using monoclonal antibody, mAb5.2. Unfortunately, 
attempts in using conventional chromatography or a combination of them could only 
partially purify the recombinant protein. In order to obtain a highly purified 
recombinant PfMSP-142 by chromatography other than immunoafFinity 
chromatography, an immobilized metal-ion affinity chromatography (IMAC) was 
employed. 
Two different isolates of Plasmodium falciparum (3D7 and FVO) were used 
in this study, A total of three recombinant BmNPV constructs, each carrying either a 
C- or N-terminal hexa-histidine tag of the PfMSP-142 gene, have been constructed. 
The recombinant BmNPVs were separately used to infect BmN cell cultures {in vitro) 
and silkworms {in vivo) to express the corresponding recombinant hexa-histidine 
tagged PfMSP-l42 recombinant proteins. The C-terminal his-tagged PfMSP-142 
expressing recombinant virus was selected for further study. A high level of 
expression was obtained when silkworm larvae were infected with this recombinant 
virus. An expression level close to 800|ag/ml hemolymph was observed. A single 
IMAC chromatographic step was employed to purify the recombinant protein and 
42% purity could be obtained. The semi-purified recombinant C-HisPfMSP-142 could 
be detected by Western blotting using the monoclonal antibody, mAb5.2. This 
antibody has been shown to bind specifically to the carboxyl terminal of the native 
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PfMSP-1 protein. By virtue of its sensitivity to reduction by mercaptoethanol 
treatment, the recombinant protein appears to have a disulphide-dependent 
conformation in the EGF-like domains similar to the native PfMSP-1. When mice 
were immunized with the recombinant C-HisPfMSP-U】，an antibody response could 
be elicited. This suggests that the recombinant protein is at least immunologically 
active. 
In the present study, we have demonstrated the feasibility in using the 
baculovirus expression system to produce a hexa-histidine tailed malarial protein. 
Further studies are needed to validate if this C-HisPfMSP-Ui protein can be used as 
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CHAPTER 1 INTRODUCTION 
1.1 Epidemiolo^ 
Malaria has probably had a greater impact on world history than any other 
infectious disease. It is a re-emerging disease that produces over 1.5 million deaths 
and 3-5 million clinical cases every year. Over 40% of the world's population live 
where there is a risk of malaria. The disease affects all age groups. But in endemic 
area, the greatest suffering is borne by children less than five years old and pregnant 
women. Some 500 million people in Africa, India, South East Asia and South 
America are exposed to endemic malaria (Figure 1). 
1» 2 Malaria disease 
Malaria is a protozoal disease caused by the blood-inhabiting parasitic 
protozoa of the genus Plasmodium. There are four human infecting malarial species, 
namely the Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and 
Plasmodium malariae. Among them, Plasmodium falciparum is the most widespread 
and pathogenic species. The parasites are transmitted by the anopheles mosquito 
which infect human (host) and insect hosts (vector) alternatively. 
3 Life Cycle of Malaria 
1. 3 .1 Exoerythrocytic stage 
Malaria infection begins when a Plasmodium-infected female Anopheles 
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Figure 2. Life cycle of the malaria parasite. 1: the exoerythrocytic stage. 2: asexual 
erythrcytic stage. 3: sexual transmission stage. 
3 
Introduction 
peripheral circulation by a bite of the mosquito. The sporozoites travel through the 
bloodstream invading hepatocytes in the first hour of inoculation and undergo an 
asexual process called exoerythrocytic schizogony in the liver to form merozoites. 
The rupture of infected liver cells releases thousand of merozoites into the 
bloodstream. 
1. 3. 2 The asexual erythrocytic stage 
Thousands of merozoites released from hepatic cells invade red blood cells 
and produce the ring stage parasites. In the erythrocytic cycle, rings obtain nutrients 
by synthesizing proteases to degrade hemoglobin into amino acids and grow to mature 
trophozoites. The trophozoites undergo schizogony to form the next generation of 
merozoites and culminate in segmentations (Figure 3). The infected erythrocytes 
rupture and liberate the merozoites that rapidly invade fresh red blood cells to 
continue the asexual blood stage cycle. Much of the pathology of malaria is caused by 
this asexual erythrocytic stage. 
1. 3, 3 The sexual transmission stage 
Some invading haploid merozoites develop into male and female gametocytes 
within the red blood cells. During blood feeding, the gametocytes are transferred to a 
female anopheline mosquito, and gametogenesis occurs in the midgut of the mosquito. 
Diploid zygote produced by fertilization then undergoes meiosis and differentiates 
into a motile ookinete. The ookinetes migrate to the midgut of the mosquito and 
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Figure 3. Illustration of different stages of Plasmodium falciparum. (Adopted from 




Sporozoites then migrate to the salivary gland of the mosquito to continue the whole 
infection cycle once the infected mosquito bites another human subject. 
1. 4 Current measure to control Malaria 
Convention measures of malaria are directed against either the infection or the 
disease. Application of insecticides, such as DDT, improved environmental 
management and the use of insecticide-impregnated bednets as well as mosquito 
repellants such as DEET are some of the effective measures taken against malaria 
infections. On the other hand, chemoprophylaxis, such as melfoquine application to 
travelers to malaria endemic areas can prevent the spreading of malaria. In this regard, 
travelers must take these drugs for four weeks after leaving the malaria-risk area to 
make sure that the medication is in the bloodstream when the parasite emerges from 
liver infection. Unfortunately, malaria infection do happen, chemotherapy of patients 
with anti-malaria drugs such as chloroquine is needed for treatment. The combined 
efforts of the above measures have once eliminated or effectively suppressed malaria 
infection in many parts of the world. However, development of resistance by 
Anopheles mosquitoes to commonly used insecticides, movement of non-immune 
populations to malaria-infected areas, armed conflicts or urban development and 
climatic as well as environmental changes have worsened the malaria problem 
(Nchinda, 1998; Muentener, Schlagenhauf & Steffen，1999). Even worse is the 
widespread of single- and multiple-drug resistant strains of Plasmodium falciparum 
6 
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(Figure 4). This makes the controlling of malaria by chemotherapy much more 
difficult (The Medical Letter, Inc., 1998; World Health Organization, 1999). 
Resistance of malaria parasites to anti-malarial drugs can be attributed to mutations of 
the enzymes that are targets of such drugs, notably the dihydrofolate reductase (Hyde, 
1990; Nzila-Mounda et al.’ 1998) and dihydropteroate synthetase (Wang et aL, 1997). 
Besides, decreased level of drug accumulation (Krogstad et al.’ 1987; Bray, Howells 
& Ward，1992), amplification and over-expression of resistance-related gene pfmdrl 
(Wilson et a/., 1989; Foote et al., 1990; Cowman, Galatis & Thompson, 1994), and 
other unknown mechanisms may all be involved in drug resistance development. 
Nevertheless, it has long been known that rechallenge of individuals in endemic area 
with Plasmodium falciparum demonstrates that a degree of protection can be 
developed against heterologous parasites and effectively against homologous parasites. 
If this protection can be mimicked by vaccination, severe illnesses and the number of 
deaths due to malaria could be reduced (Riley, 1995). As conventional anti-malaria 
strategies have lost their effectiveness, vaccine development appears to be an 
attractive means to control the disease. 
5 Anti-malaria Vaccine Candidate 
Anti-malaria vaccine strategies are targeted towards the surface antigens of 
parasite expressed at different stages of their life cycle (Nussenzweig et al.’ 1985). A 

































































































































































antigens based on merozoite surface protein such as the merozoite surface protein 
(MSP-1), the erythrocytic-binding antigen (EBA-175), the apical membrane antigen-1 
(AMA-1), and the ring-infected erythrocytic surface antigen (RESA) (Moreno & 
Patarroyo, 1995); In addition, antigens expressed in the sexual stages such as 
gametocytes (vertebrate host) Pfs230, Pfs48/45, Pfg27 and ookinetes (vector host) 
Pfs25 and Pfs28 (Gozar et a!.’ 2001; Lobo, Dhar & Kumar，1999) have also been 
studied. As much of the pathology of malaria is caused by the asexual blood stage of 
the organism, vaccine targets to this stage is believed to be effective in reducing 
complications of the disease and as well as preventing death. From previous studies, it 
has been shown that mice immunized with native and recombinant merozoite surface 
protein were protected from the lethal challenge of the parasite (Chang et al., 1989; 
Ling, Ogun & Holder，1994), This protection appears to be antibody mediated as a 
monoclonal antibody on passive immunization is effective against blood stage 
challenge infection (Spencer Valero et al,’ 1998; Freeman, Trejdosiewicz & Cross, 
1980). In non-human primate model, Actus monkeys immunized with merozoite of 
human malaria Plasmodium falciparum were completely protective against a lethal 
challenge of the homologous erythrocytic malaria parasites (Siddiqui, 1977). As the 
major merozoite surface proteins were discovered to elicit antibody response from 
human during a natural Plasmodium falciparum infection (Gentz et al.’ 1988)，they 
are of particular interest as potential anti-malaria vaccine candidates. 
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1. 6 Anti-ervthrocvtic malaria vaccine MSP-1 
1. 6 .1 Structure of MSP-1 
The Plasmodium falciparum major merozoite surface protein is a 195kDa polypeptide 
systhesized at the erythrocytic schizont stage (Holder & Freeman，1982). It is 
anchored onto the merozoite surface via a glycosylphosphatidylinositol (GPI) 
membrane anchor (Haldar, Ferguson & Cross, 1985; McConville & Ferguson，1993). 
MSP-1 exists primarily in two allelic forms and at the asexual erythrocytic halpoid 
stage only one of the two allelic forms (PNG-MAD20 and Wellcome type) will be 
present. Since, MSP-1 is polymorphic, intragenic recombination has been suggested 
to be the mechanism to generate new MSP-1 alleles in the progeny (Kerr, 
Ranford-Cartwright & Walliker，1994). MSP-1 protein can be divided into 17 blocks 
of sequences with different degree of sequence variation (Tanabe et al.’ 1987) (Figure 
5). A short segment of amino acids composed of the tripeptide repeats is located at the 
amino terminal region of MSP-1. Distinct from the amino terminal part, the carboxyl 
terminal 19kDa fragment (block 17) of MSP-1 (MSP-119) is highly conserved 
(Jongwutiwes, Tanabe & Kanbara, 1993; Kang & Long, 1995). On the basis of amino 
acid sequence similarity, two epidermal growth factor (EGF)-like motifs are presented 
on MSP-119 and they are highly conserved among different species of malaria 
(Blackman et al, 1991) (Figure 6). In these motifs, six cysteine residues form three 
disulphide bonds that are responsible for the formation of EGF-like domain (Figure 7) 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7. Comparison of the stereo view of MSPl domains. The first domain of 
MSPlinv is shown in green and the second domain in purple. The two images are 




1. 6. 2 Processing ofMSP-1 
Maturation of MSP-1 occurs in two distinct proteolytic steps. The primary step at the 
end of schizogony leads to a noncovalently associated complex of MSP-1 derived 
peptides, including MSP-Us, MSP-130，MSP-138 and MSP-142 (Holder & Freeman， 
1984; McBride & Heidrich，1987). During the erythrocytic invasion, secondary 
processing releases the N-terminal peptide complex (MSP-133), yielding the 
C-terminal MSP-119 glycosylphosphatidylinositol (GPI) membrane anchored peptide, 
which remains on the merozoite surface after invasion (Blackman et al., 1990) (Figure 
8). The sequence of MSP-119 is highly conserved among different strains of malaria . 
It carries the two epidermal growth factor EGF-like domain (Blackman et al.’ 1991). 
The MSP-133 fragment, together with other polypeptides derived from the primary 
processing of MSP-1, is shed into the extracellular milieu (Blackman & Holder，1992). 
The actual function of MSP-1 protein remains unknown. However, it has been 
demonstrated that MSP-119 is specifically carried into the red blood cell and that 
antibody to this fragment can inhibit invasion. Other studies have shown that 
antibodies against MSP-1 can interfere with parasite growth in vitro (Blackman et al., 
1990; Cooper, Cooper & Saul，1992) and in vivo (Boyle et al., 1982; Lew et al.’ 
1989). It was suggested that processing of MSP-1 and the formation of MSP-119 are 
essential step for merozoite invasion to proceed. 
14 
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Figure 8. Schematic diagram showing secondary processing of the Plasmodium 
falciparum MSP-1. (A) MSP-1 is present on the newly released surface as a complex 
of four polypeptides of -83, 30，38 and 42kD (MSP-183, MSP-I30, MSP-ljg and 
MSP-142). MSP-142 is membrane bound through a glycosylphosphatidylinositol. (B) 
At or just before invasion, secondary processing occurred to produce MSP-119 
containing EGF-like domain. These modules remained on merozoite surface after 




1. 6. 3 MSP-I42 as a vaccine candidate 
Among most of anti-malaria vaccine candidates, MSP-1 is the most studied 
one and is the focus in the development of anti-erythrocytic stage vaccine. MSP-1 
from Plasmodium falciparum (PfMSP-1) is the most frequent studied protein because 
it is from the malaria species which infects human and causes the most severe 
symptoms and death in endemic area. Congenic mice with different genetic 
backgrounds were capable of producing PfMSP-1 specific antibodies by immunizing 
with PfMSP-1 protein, indicating the immune response was not MHC 
haplotype-restricted (Chang et al., 1989). In subsequent rodent experiments, it has 
been shown that mice immunized with recombinant Plasmodium yoelii MSP-119 are 
protected against an infection challenge (Daly & Long, 1993). This protection appears 
to be antibody mediated (Ling et al., 1997) as monoclonal antibodies generated from 
mice have been demonstrated to react with the C-terminal cysteine region of P. yoelii 
MSP-1. Certain mAb against Plasmodium falciparum MSP-119 that inhibit 
erythrocytic invasion in vitro also possess the ability to inhibit the secondary 
processing of PfMSP-142 (Blackman, M.J. et al 1994). This secondary process 
involves proteolytic cleavage of the MSP-142 into 33kDa and 19kDa fragments and 
only the latter peptide would remain on the merozoite surface after entry into RBC 
(Figure 8B). In addition, transfusion of specific antibody against MSP-1 to recipient 
was shown to be effective in protection of animals challenged with blood stage 
16 
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parasite (Majarian et al., 1984; Spencer Valero et al,, 1998). In non-human primate, 
the first successful immunization of experimental monkey against a human malaria 
parasite was reported in 1977 (Siddiqui, 1977). Later, PfMSP-1 immunization was 
further confirmed to be effective in protecting monkeys against a lethal malaria 
parasite challenge (Hall et al., 1984; Siddiqui et al, 1986; Siddiqui et al., 1987). 
Moreover, sera from these PfMSP-1 immunized monkeys and rabbits could strongly 
inhibit parasitic growth in vitro (Hui & Siddiqui，1987). Most importantly, 
immunological cross-reactivity was observed from PfMSP-1 proteins isolated from 
two different strains of malaria and this was believed to be due to the recognition of 
the conserved determinants. Thus, a MSP-1 based vaccine may be effective against 
blood stage infection from an array of parasite isolates (Hui, Hashimoto & Chang, 
1992). 
Subsequent findings showed that anti-PfMSP-1 antibodies were mainly 
reactive towards the carboxyl-terminal processing fragment PfMSP-142, and more 
specifically, the PfMSP-119 fragment (Hui et al, 1996; Ling, Ogun & Holder，1994). 
A recombinant PfMSP-142 was expressed by the baculovirus Autographa Californica 
Nuclear Polyhedrosis Virus (AcNPV) (denoted AcNPVp42) was shown to be highly 
immunogenic (Hui et al, 1993; Chang et al, 1992). And anti-BVp42 antisera raised 
from rabbits have shown high cross-reactivity with PfMSP-1 of different isolates of 
Plasmodium falciparum. Moreover, the antisera could completely inhibit parasitic 
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growth in vitro. In field studies, human sera collected from malaria endemic area 
could recognize the AcNPVp42 to the extent as PfMSP-1. High antibody titer was 
produced when Aotus monkeys were immunized with BVp42. Their antisera were 
also cross-reactive with PfMSP-1 from different isolates of Plasmodium falciparum 
and were highly inhibitory to parasitic growth (Chang et al, 1996). Most importantly, 
immunized monkeys were protected against the challenge of erythrocytic malaria 
parasites. In addition, the T-lymphocytes of these immunized animals could be 
induced to proliferate significantly by purified PfMSP-1 protein and whole parasites, 
indicating that PfMSP-1-specific T cells were involved in the immunity against 
erythrocytic malaria parasites and they were effectively primed by AcNPVp42. In 
contrast, the same PfMSP-142 polypeptide, when expressed as a yeast intracellular 
product (denoted Yp42), could not be recognized by the anti-PfMSP-1 and 
anti-AcNPVp42 antisera (Chang et al.’ 1992). Moreover, significantly lower 
anti-Yp42 antibody titer was obtained when rabbit were immunized with this protein 
and the antisera raised showed little cross-reactivity with PfMSP-1 and fixed whole 
parasites. It was suggested that the native disulphide-dependent conformational 
epitopes on PfMSP-142, which are formed by the two EGF-like domains, were poorly 
expressed in yeast; while they were authentically expressed in the baculovirus 
expression system. The above immunological evidence, together with other data (Hui 
et al, 1992; 1993; 1996), strongly indicate that the two EGF-like domains in MSP-119 
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constitute the major target of antibody response. Hence, PfMSP-li9 was evaluated as 
the minimal fragment for a PfMSP-1-based vaccine (Kaslow, Hui & Kumar, 1994). 
Rabbits immunized with an active yeast-expressed recombinant PfMSP-119 protein 
(YMSP-119) produced a high antibody titer cross-reacting with PfMSP-1. However, 
the antibodies were found to be ineffective in inhibiting malaria parasites. Moreover, 
T-lymphocytes from BVp42-protected Aotus monkeys (Chang et al., 1996) and from 
immune human donors (Egan et ai, 1997) could not be effectively stimulated to 
proliferate by YMSP-119. Thus, the relevant T-cell epitopes responsible for induction 
T-cell response was probably absent in the PfMSP-119 fragment. The use of this 
minimal fragment as an anti-malarial vaccine is therefore not favorable. 
It has been shown that native protein conformation is essential for antigenicity, 
immunogenicity and induction of growth-inhibitory antibodies (Locher & Tarn, 1993). 
Bacterial expressed PfMSP-1 protein and its processing fragment (Holder, Freeman & 
Nicholls, 1988; Herrera et aL, 1990; Etlinger et al., 1991) and PfMSP-1 synthetic 
peptides (Patarroyo et aL, 1987) have been shown to be less effective in inducing 
immunity and protection to malaria. The reason for this maybe due to the lack of 
proper secondary and tertiary structure required for the induction of protective 
immunity. For example in E.coli’ the formation of disulphide bond critical for native 
conformation in the highly conserved EGF like domain was probably not possible 
(Bialy etal 1987). 
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From the above studies, it can be concluded that for producing a vaccine base 
on PfMSP-1, the main consideration is to recreate the important conformational 
epitopes that can mimic the immunogenicity and protective efficacy of the native 
protein. Among the common protein expression systems available, the baculovirus 
expression system certainly has distinct advantages over others in this respect. 
1. 7 Baculovirus Expression System 
1. 7.1 Characteristics of baculoviruses 
Baculoviruses are a diversified group of closed-circular double-stranded DNA 
viruses of the family Baculoviridae, which are found mostly in insects. The haculo 
portion of the name refers to the rod-shaped capsids of the virus particles (0’ Reilly et 
a/.，1994). The Baculovihdae can be divided into two sub-families: the 
Eubaculovirinae (occluded baculoviruses) and the Nudihaculovihnae (non-occluded 
baculoviruses). The Eubaculovirinae produces crystalline proteinaceous structures 
called occlusion bodies, which are absent in the Nudihaculovirinae (Vialard, Arif & 
Richardson, 1995). The Eubaculovirinae subfamily is made up of two genera: 
granulosis viruses (GVs) and nuclear polyhedrosis viruses (NPVs). The virus used in 
this study, the Bombyx mori Nuclear Polyhedrosis Virus (BmNPV), is a NPV，and it 
will be the focus of the following discussion. Most baculoviruses isolated are very 
host-specific, and the majority of Eubaculovirinae have been isolated from larvae of 
the Lepidoptera family (for example, moths and butterflies). Baculovirus vectors 
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commonly used in recombinant protein expression include the Autographa californica 
Nuclear Polyhedrosis Virus (AcNPV) and BmNPV. 
1. 7. 2 Infection cycle of baculovirus 
The occlusion bodies containing mature virus particles are taken up by a 
susceptible larval host as food contaminants. The alkaline environment of the larval 
midgut dissolves the occlusion bodies and releases the virus particles. Primary 
infection of the midgut epithelial cells occurs through a receptor-mediated membrane 
fusion process. The nucleocapsids are targeted to the nucleus where replication and 
transcription of the viral DNA occur. Budding viruses from the initially infected cells 
cause secondary infection to adjacent cells through a receptor-mediated adsorptive 
endocytosis mechanism. At a late stage of the infection process, the mature virus 
particles are multiply packed into occlusion bodies which comprised mainly of a 
protein called polyhedrin. Finally, the infected larva dies and disintegrates. The 
occluded viruses, which are protected by the occlusion bodies, are dispersed from the 
dead bodies and consumed by another susceptible larva, thereby reinitiating a new 
infection cycle (Figure 9). 
1. 7. 3 Control of viral gene expression in virus-infected cells 
Baculovirus gene expression is regulated in a cascade-like fashion. The temporal 
regulation allows the grouping of baculoviral genes into three phases during infection: 
early (E), late (L) and very late (VL). The E genes are transcribed prior to viral DNA 
replication and generally encode proteins with regulatory functions (e.g. EGT and 
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HEL). The L genes are activated before the VL genes and are maximally transcribed 
between 12 and 24 hours post-infection. This catalogue of genes encode structural 
proteins of budded virus and occlusion-derived virus (e.g. P39 and GP41). The VL 
genes, which are under the control of strong promoters, are hyper-expressed following 
the activation of the L genes and remain active from 48 hours post-infection onward. 
VL proteins are those involved in the processes of occlusion and cell lysis; e.g. 
polyhedrin and PIO (Figure 10). 
1. 7. 4 Merits of Baculovirus Expression System 
Baculovirus expression system has been successfully employed to express 
biologically active recombinant proteins for agricultural and pharmaceutical use. For 
examples, human a-interferon (Maeda et al., 1985), human granulocyte-macrophage 
colony-stimulating factor (Shi et al.，1996) and grass carp growth hormone (Ho et al., 
1998). There are a number of advantages in using baculovirus as an expression vector 
(Maeda, 1989, 1994). Firstly, being eukaryotic origin, the insect cells can correctly 
fold and modify the expressed foreign proteins with their biological activities retained. 
Secondly, the double-stranded DNA genome of the virus can be easily manipulated 
by general molecular biology techniques and the rod-shaped viral capsid is rather 
"flexible" in accommodating large DNA insert. In this regard, the polyhedrin gene 
(polh) is the best choice because it is non-essential for viral reproduction and is driven 


































































































































































































































































































































































































































































indicate the successful insertion of a foreign gene under the control oipolh promoter. 
Thirdly, the recombinant baculoviruses cannot survive in the environment owing to 
the lack of protection by occlusion bodies, thus posing less biohazards. Because of the 
advantages mentioned, baculovirus expression system seems to be an ideal system for 
the expression of the PfMSP-142 protein. 
1. 8 hexa-histidine tagged fusion protein 
Protein with a hexa-histidine tail can bind to affinity column with metal ion 
chelating group. The poorly immunogenic hexa-histidine tail enables a recombinant 
protein to be used as antigen to generate antibody against protein of interest without 
prior removing it. At pH8.0, the his-tag is small, uncharged, and therefore does not 
generally affect secretion, compartmentalization, or folding of the fusion protein 
within the cell. In most cases, the 6xHis tag does not interfere with the structure or 
function of the purified protein as demonstrated in a wide variety of proteins, 
including enzymes (Oswald et al, 1994)，transcription factors (Janknecht et al, 1991)， 
and engineered antibodies (Watkins et al., 1997). As mentioned his-tag labeled 
proteins have high affinity for metal-chelating surfaces such as Iminodiacetic acid 
(IDA), therefore metal-chelating affinity column can be adapted for downstream 




1. 9 IMAC 
Immobilized metal affinity chromatography (IMAC) was first used to purify 
proteins in 1975 (Porath et al., 1975) using the chelating ligand iminodiacetic acid 
(IDA, Figure 11). IDA is first charged with the transition metal ions (Zn ，Cu2+, Ni ， 
Ca2+，Co2+，Mg2+ etc.) to form a chelate. Proteins will bind to the gel contingent upon 
the presence of surface histidine, cysteine and tryptophan residues which have an 
affinity for the chelated metal ions. The binding strength is affected predominately by 
the species of metal ion and pH of the buffers. Since the metal ions are strongly bound 
to the matrix, the adsorbed protein can be eluted by competitive elution (imidazole 
concentration gradient) and lowering the pH. 
1. 10 Aim of study 
AcNPV has been successfully used to produce a recombinant AcNPVp42 
protein for vaccination of animals against erythrocytic malaria (Chang et al.’ 1992). 
Our laboratory has also developed an efficient BmNPV expression system by 
infecting silkworm larva. The BmNPV produced recombinant BVp42 was confirmed 
to be biologically and immunologically active as that produced by the AcNPV system. 
The BmNPV (silkworm system) has an advantage over AcNPV (cell culture system) 
to produce a large quantity of recombinant protein with lower cost. However, the 
recombinant protein produced in the silkworm hemolymph was difficult to be purified 
using conventional chromatography. It could only be efficiently purified by 
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Figure 11. Interaction between metal ion charged chelating matrix and 6xHis 
polypeptide. A. Showing two different chelating matrix iminodiacetic acid (IDA) and 
Nitrotriacetic acid (NTA) interacting with nickel ion (Ni^^). B. Schematic diagram 
showing the interaction between the matrix and 6xHis protein through the charged 
metal ion. C. Showing neighboring residue in the 6 His-tag and Ni-NTA matrix. (Ad pted from Handbooks a d Protocols online provided by Qi gen;http://www.qiagen.com/literature/handbooks/qxp/qxpdayiO 17396_HBQXP_Intro.pdf) 
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immunoafFinity chromatography using monoclonal antibody, mAb5.2. In the 
preparation of materials for human clinical trial, proteins purified by immunoafFinity 
chromatography require stringent demonstration of safety as required by agencies 
such as the Food and Drug Administration (FDA) of USA. For instance, if using 
murine monoclonal antibodies (mAb5.2), the affinity column must be free of 
contaminants such as DNA and viruses, and the purified protein products must be free 
of immunoglobulins that may leach from the column. To avoid the regulatory issues 
of using immunoafFinity chromatography, we explored and evaluated if immobilized 
metal affinity chromatography could be used to purify a his-tag recombinant 
PflVISP-l42 protein. 
In this study, three recombinant BmNPV have been constructed, two of them 
were encoded by the 3D7 strain and the other by the FVO strain of Plasmodium 
falciparum. A honeybee melittin signal peptide was used as part of the encoding 
sequence in the three constructs to transport the recombinant protein extracellularly 
(secretary recombinant protein). The hexa-histidine tag was introduced either into the 
C- or the N- terminal of the gene. 
This thesis describes the construction, purification, expression, purification 
and characterization of the recombinant his-tagged PfMSP-142 proteins developed in 
the course of our research. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials 
2 .1 .1 Reagents for Bacterial Culture 
2 . 1 . 1 . 1 Luria-Bertani (LB) medium 
It was prepared by dissolving lOg bacto-tryptone (Difco, Detroit, MI), 5g 
bacto-yeast extract (USB, Cleveland OH), and lOg NaCl in IL dH20. The medium 
was autoclaved for 20 minutes at 121°C and l.lkg/cm^ on liquid cycle before use. 
2.1. 1. 2 Ampicillin (Ap) solution 
Ampicillin (Ap) was purchased from USB (Cleveland, OH) and 50mg/ml 
stock solution in dHzO was prepared. The stock solution was sterilized by filtration 
through a 0.2}im pore-size membrane filter (Schleicher & Schuell GmbH, Dassel, 
Germany). One-millilitre aliquots were made and were stored at -20°C. 
1.1. 3 LBAp medium 
It was sterile LB medium supplemented with Ap at lOOjig/ml medium. 
2.1 .1 . 4 LB and LBAp agar plates 
LB agar medium was prepared by the addition of agar (Sigma, St. Louis, MO) 
to LB medium to 1.5% (w/v) before autoclaving. For LBAp agar medium, Ap was 
supplemented at lOOjig/ml agar medium after autoclaving. Luke-warm agar medium 
was poured into 90mm disposable petri dishes at ~20ml/dish. The agar plates were 
allowed to set and stored at room temperature. 
2.1 .1 . 5 SOB medium 
A solution of 2% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, lOmM 
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NaCl, and 2.5mM KCl was prepared and sterilized by autoclaving. Afterwards, a 
filter-sterilized MgCb and MgSO* solution (IM each) was added to a final 
concentration of lOmM each for the final SOB medium. 
2.1 .1 . 6 SOB and SOBAp agar plates 
SOB and SOBAp agar plates were prepared in the same way as LB and LBAp 
agar plates. 
2.1 .1 . 7 SOB and SOBAp agar stabs 
SOB agar medium was SOB medium supplemented with agar to 0.8% (w/v). 
For SOBAp agar medium, Ap was added at 100|ig/ml to a sterilized SOB agar 
medium. Three millilitres of the medium was aliquoted into each autoclaved glass 
vials with screw-on caps fitted with rubber gaskets. The stabs were allowed to set at 
room temperature at a 45° inclination. After incubating at 37�C for 24 hours to check 
for contamination, the agar stabs were stored in the dark at room temperature until 
use. 
2.1 .1 . 8 SOC medium 
It was SOB medium supplemented with 20mM glucose solution sterilized by 
0.2|im pore-size membrane filtration. 
2.1. 2 Reagpnts for Miniprep ofPlasmid DNA 
2.1. 2 .1 Solution I 
It consisted of 50mM glucose, 25mM Tris-HCl at pH8.0 and lOmM EDTA. 
The solution was autoclaved before use. It was stored at 4°C. 
2.1. 2. 2 Solution H 
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It was prepared by dissolving 1% (w/v) SDS in 0.2M NaOH solution. 
2.1. 2. 3 Solution m 
It consisted of 60ml 5M potassium acetate solution and 11.5 ml glacial acetic 
acid and was made up to 100ml with sterile dHzO. 
2.1. 2. 4 TE buffer 
It was a solution of lOmM Tris-HCl at pH8.0 and ImM EDTA. The buffer 
was autoclaved before use. 
2.1. 3 Reagents for Plasmid DNA Preparation using Oiagen® Plasmid Midi Kit 
2.1. 3 .1 Buffer PI 
It consisted of 50mM Tris-HCl at pH8.0, lOmM EDTA and 100|ig/ml of 
RNase A. The buffer was stored at 4°C after the addition of RNaseA. 
2.1. 3. 2 Buffer P2 
It consisted of200mM NaOH and 1% SDS. 
2.1. 3. 3 Buffer P3 
It was 3M potassium acetate at pH5.5. 
2.1. 3. 4 Buffer QBT 
It consisted of750mMNaCl, 50mM MOPS at pH7.0, 15% ofethanol and 
0.15% Triton X-100. 
2.1. 3. 5 Buffer QC 
It consisted of IM NaCl, 50mM MOPS at pH7.0 and 15% ofethanol. 
2.1. 3. 6 Buffer QF 
It consisted of 1.25M NaCl, 50mM Tris-HCl at pH8.5 and 15% ofethanol. 
2. 1. 4 Reagents for Agarose Gel Electrophoresis 
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2.1. 4. 1 Tris-acetate-EDTA (TAE) electrophoresis buffer 
A 50x stock solution was prepared by dissolving 242g Tris base in 800ml 
ddH20. Afterward, 100ml 0.5M EDTA solution (pH8.0) and 57.1ml glacial acetic 
acid were added. The solution was made up to IL with ddHzO and it was diluted 
50-fold before use. 
2.1. 4. 2 Tris-borate-EDTA (TBE) electrophoresis buffer 
A lOx stock solution was prepared by dissolving 108g Tris base, 55g boric 
acid in 800ml ddHzO. Forty millilitres of 0.5M EDTA solution, pH8.0，were added. 
The solution was made up to IL with ddHsO and was diluted 10-fold before use. 
2. 1. 4. 3 DNA sample loading buffer 
A 6x buffer was prepared by mixing 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol FF and 40% (w/v) sucrose solution in sterile dHzO. The buffer 
was stored at 4°C. 
2. 1. 7 Reagents for Insect Cell Culture and Virus Work 
2.1. 7.1 Grace's insect cell culture medium 
It was purchased from GibcoBRL (Grand Island, N. Y.) in liquid form in a 
package size of SOOml/bottle. The medium was supplemented with 500mg/L CaCb, 
2800mg/L KCl, 3330mg/L lactalbumin hydrolysate, 3330mg/L yeastolate and 
L-glutamine. The medium was stored at 4�C. 
1. 7. 2 Fetal bovine serum (FBS), certified grade, originated from USA 
It was purchased from GibcoBRL (Grand Island, N. Y.) in a package size of 
SOOml/bottle. Just before use, the serum was heat-inactivated (HIFBS) at 56°C for 30 
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minutes. Aliquots of 20ml were prepared and stored at -20°C. 
2.1. 7. 3 Antibiotic-antimycotic (lOOx) 
It was also purchased from GibcoBRL (Grand Island, N. Y.) in liquid form in 
a package size of lOOml/bottle. It contained 10,000 units of penicillin G, 10,000}ig 
streptomycin sulphate and 2,500^g amphotericin B (Fungazone®) in 0.85% saline. 
Five-millilitre aliquots of this antibiotic-antimycotic (PSF) were made and stored at 
-20°C before use. 
2.1. 7. 4 Complete insect cell culturing medium 
It was prepared by supplementing Grace's insect cell culture medium with 1% 
(v/v) PSF and 10% (v/v) fflFBS. 
2.1. 7. 5 Infection medium 
It was prepared by supplementing Grace's insect cell culture medium with 1% 
(v/v) PSF and 1% (v/v) HIFBS. 
2.1. 7. 6 Recovery culture medium 
It was Grace's insect cell culture medium supplemented with 20% (v/v) 
HIFBS. 
2.1. 7. 7 Agarose solution 
A 2.5% (w/v) low temperature, low EEO sulphate content SeaKem® LE 
agarose solution (FMC® BioProducts, Santa Rosa, CA) was first prepared in ddHzO 
and autoclaved. It was melted in a microwave oven before use. 
2. 1. 7. 8 Agarose overlay medium 
The melted agarose solution and the complete insect cell culture medium were 
separately warmed in a 50°C water bath. Just before overlaying onto infected BmN 
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cells, 1ml of the agarose solution and 3 ml of the complete insect cell culturing 
medium were mixed thoroughly in a sterile 5 ml snap-capped tube to constitute the 
agarose overlay medium. 
2.1. 7. 9 Neutral red-agarose overlay medium 
Four millilitres of Neutral-red solution at 3.3g/L (Sigma, St. Louis, MO) were 
premixed with 6ml 2.5% SeaKem® LE agarose solution. The mixture was melted 
before use. One millilitre of the mixture was added to 3ml pre-warmed complete 
insect cell culture medium to constitute the Neutral red-agarose overlay medium. 
2.1. 7.10 Occlusion body lysis buffer 
It consisted of 0. IM NaCOs and 0.05M NaCl. It was autoclaved before use. 
2. 1. 7. 11 DTT solution 
A 250mM stock solution of dithiothreitol (DTT) was prepared by dissolving 
0.7725g DTT in 20ml O.OIM sodium acetate solution, pH5.5. The DTT solution was 
sterilized by 0.2|im pore-size membrane filtration. One-millilitre aliquots were 
prepared and kept at -20°C. 
2.1. 7.12 PBS for insect cell culture 
It was prepared by dissolving 8g NaCl, 0.2g KCl，1.44g Na2HP04 and 0.24g 
KH2PO4 in a final volume of IL dHaO. The pH of the buffer was adjusted to 7.4 with 
IM HCl and it was autoclaved before use. 
2. 1. 8 Reagents for IMAC purification 
2.1. 8 .1 Imidazole 
Two different brands of imidazole were used. One was purchased from Sigma 
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in powder form of package size of lOOg/bottle. This imidazole is in hydrochloride 
form. The other one was purchased from USB in pure powder form of IKg/ bottle. 
2.1. 8. 2 Start buffer for BMAC purification 
Start buffer solution was prepared by dissolving 3.56g Na2HP04 (20mM) and 
116.88g NaCl (2M) in a final volume of IL dHaO. The pH is around 8.2 without 
adjusting and it was filtered with 0.45^m filter before use. The solution was stored at 
4°C. 
2.1. 8. 3. Regeneration buffer 
It consist of 0.05M EDTA (reagent grade) and 0.5M NaCl in dHaO. 0.45^m 
filtered before use and stored at room temperature. 
2.1. 9 Reagents for SDS-PAGE 
2.1. 9.1 Stacking gel and resolving gel 
Solutions for making gels were prepared according to Sambrook et al (1989). 
For a 30% acrylamide mix, a working solution of 29% (w/v) acrylamide plus 1% (w/v) 
bis in ddH20 was prepared. It was filtered through a 0.45nm pore size membrane 
filter before use. The solution was stored at 4 � C in a dark bottle. Other reagents were 
prepared by dissolving the corresponding chemicals in ddHaO. 
2.1. 9. 2 Tris-glycine electrophoresis buffer 
A 5x stock solution was prepared by dissolving 15.Ig Tris base and 94g 
glycine in 900ml (IH2O. Fifty millilitres 10% (w/v) SDS solution was added, and the 
volume was adjusted to IL with dHzO. The stock solution was diluted 5-fold before 
use. 
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2.1. 9. 3 Sample loading buffer 
A 2x working solution was prepared with 4% (w/v) SDS, 125mM Tris-Cl 
(pH6.8), 30% (v/v) glycerol and 0.002% (w/v) bromophenol blue. For reducing 
disulphide bonds of proteins, 5-10% (v/v) P-mercaptoethanol (Sigma, St. Louis, MO) 
was added just before use. 
2.1. 9. 4 SDS-PAGE staining solution 
It was prepared by dissolving 0.25g Coomassie Brilliant Blue R-250 (Sigma, 
St. Louis, MO) in 90 ml 1: 1 (v/v) methanol: dHzO mixture and 10ml glacial acetic 
acid. 
2. 1. 9. 5 SDS-PAGE destaining solution 
It was prepared by mixing 250ml ethanol with 80ml glacial acetic acid and 
made up to IL with dHzO. 
2.1. 9. 6 Silver stain fixative enhancer solution 
It was prepared according to the instructions of the Silver Stain Plus Kit 
(Bio-Rad, Hercules, CA). It consisted of 10% (v/v) fixative enhancer concentrate 
(provided by the kit), 50% (v/v) reagent grade methanol and 10% (v/v) reagent grade 
glacial acetic acid in ddHzO. 
2.1. 9. 7 Silver stain staining substrate solution 
It was prepared according to the instructions of the Silver Stain Plus Kit 
(Bio-Rad, Hercules, CA). Just before use, 1.5ml each of the silver complex solution, 
reduction moderator solution, and image development reagent (all provided by the kit) 
were mixed and made up to 25ml with ddHzO (Solution 1). At the same time, a 4% 
(w/v) development accelerator solution (Solution 2) was also freshly prepared by 
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dissolving the development accelerator powder (provided by the kit) in ddHiO. The 
two solutions were mixed together to constitute the staining substrate solution. 
2.1 .10 Reagents for Western Blotting 
2. 1.10. 1 Bjerrum and Schafer-Nielsen transfer buiTer 
It was prepared by dissolving 5.82g Tris and 2.93g glycine in a minimal 
volume of ddHjO. 3.75ml 10% (w/v) SDS solution and 200ml analytical grade 
absolute methanol were then added. The final volume was made up to IL with ddHzO. 
The pH of the buffer ranged from 9.0 to 9.4. 
2.1.10. 2 PBS 
A 5x stock solution was prepared by dissolving 40g NaCl, Ig KCl, 7.2g 
Na2HP04 and 1.2g KH2PO4 in a final volume of IL dRjO. The stock solution was 
diluted 5-fold with pH adjusted to 7.4 with HCl before use. 
2.1.10. 3 Wash buffer (PBST) 
It was Ix PBS containing 0.05% (v/v) Tween® 20 (USB, Cleveland, OH). 
2.1.10. 4 Blocking solution 
It was PBST containing 5% (w/v) non-fat dried milk powder. 
2.1.10. 5 AP substrate buffer 
It was a buffer of O.IM Tris, O.IM NaCl and 5mM MgClj. The pH of the 
buffer was adjusted to 9.5 with IM HCl. 
2.1.10. 6 AP substrate solution 
Nitro blue tetrazolium (NET) solution was prepared by dissolving lOmg (if 
tablet was used, one tablet of NET (Sigma, St. Louis, MO) in 1ml ddHjO. The 
solution was wrapped in aluminum foil and kept at -20°C. 
37 
Materials A nd Methods 
5-Br0m0-4-chl0r0"-3-ind0lyl phosphate (BCIP) solution was prepared by dissolving 
50mg BCIP (Sigma, St. Louis, MO) in 1ml ddHzO and kept at -20°C. Just before use, 
300|il NBT solution and 30^il BCIP solution were added to 10ml AP substrate buffer 
(for each 7 x 5 cm� membrane) to constitute the AP substrate solution. 
2.1.11 Reagents for ELISA 
2 .1 .11 .1 ELISA coupling buffer 
It was prepared by dissolving 1.6g NaaCOs and 2.9g NaHCOs in IL dHaO. 
The pH of the solution was adjusted to 9.6 with IM HCl. 
2.1.11. 2 Wash buffer 
It was PBST. 
2.1.11. 3 Blocking buffer (PBSTM) 
It was PBST containing 3% (w/v) non-fat dried milk powder. 
2.1.11. 4 Saturation buffer (PBS/BSA) 
It was prepared by dissolving 1% (w/v) bovine serum albumin (BSA; Sigma, 
St. Louis, MO) in Ix PBS pH7.4. 
2.1.11. 5 Secondary antibody buffer (PBST/BSA) 
It was prepared by dissolving 1% (w/v) BSA in PBST. 
2.1.11. 6 Horseradish peroxidase (HRP) substrate buffer 
It was lOOmM trisodium citrate solution with pH adjusted to 4.1 with IM HCl. 
2.1.11. 7 HRP substrate mix 
A 5Ox ABTS stock solution was prepared by dissolving 0.499g 2， 
2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (ABTS; Sigma, 
St. Louis, MO) in 20ml HRP substrate buffer. One-millilitre aliquots were prepared 
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and kept at -20°C. Just before use, one aliquot of ABTS was warmed at 37°C. For 
each millilitre of substrate solution, 200|il 50x ABTS solution and 1.4|il 30% (v/v) 
H2O2 were made up to 1ml with HRP substrate buffer. 
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2. 2 Methods 
2. 2 .1 General Techniques in Molecular Cloning 
2. 2. 1. 1 Purification of PGR products or restricted DNA fragments by the 
GeneClean® m Kit (BiolOl, Inc., Vista, CA) 
PCR products or restricted DNA fragments were separated on TAE agarose 
gel stained with 10|j.g of ethidium bromide (EtBr) and visualized by UV 
trans-illumination (FotoDyne Inc.). Gel with the target DNA band was excised with a 
cutter and saved in a sterile 1.5ml eppendorf tube. Three volumes (v/w) of 6M Nal 
were added, and the tube was immersed into a 55°C water bath until the gel melted 
completely. The gel solution was incubated at room temperature for 5 minutes with 
occasional mixing after the addition of 10-20|al EZ-Glassmilk®. The Glassmilk pellet 
was saved by centrifuging at 13,000 rpm at room temperature for 20 seconds. 0.5-1ml 
ice-cold NEW Wash solution was added to wash the pellet. The tube was 
re-centrifuged at 13,000 rpm at room temperature for 20 seconds and the pellet was 
saved. The washing process was repeated twice. After removing the residual amount 
of NEW Wash solution, the Glassmilk pellet was resuspended in 10-20|il (as that of 
EZ-Glassmilk® added) Elution Solution™ provided by the kit. The supernatant was 
saved after centrifuging at 13,000 rpm at room temperature for 30 seconds. The 
elution process was repeated once and the supernatants were pooled. Purified DNA in 
the supernatant was examined by agarose gel electrophoresis. 
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2. 2.1. 2 Preparation of competent E. coli for transformation (Hanahan D., 1986) 
E. coli strain DH5a or JM109 was streaked from agar stabs onto SOB agar 
plates the day before the preparation of competent E. coli cells. The streaked plates 
were incubated at 37°C for 16-18 hours. Colonies of 2-3 mm in diameter were picked 
and inoculated into SOB medium at one colony per 10ml medium in a sterile conical 
flask. The inoculum was shaken at 37°C at 250 rpm until ODeoo reading reached 
0.35-0.6. The bacterial suspension was transferred to a 50ml Falcon tube and chilled 
on ice for 15 minutes. The bacteria were then harvested by centrifugation at 3,000 
rpm at 4°C for 15 minutes. RFl solution was added to resuspend the bacterial pellet in 
a volume one-third of the original inoculum. The resuspended bacteria were kept on 
ice for 30 minutes and then centrifuged at 3,000 rpm at 4°C for one hour. After 
discarding the supernatant, RF2 solution was added to resuspend the bacteria in a 
volume 1/12.5 of the original inoculum. After keeping on ice for 15 minutes, the 
bacteria were distributed into 200|il-aliquots in pre-chilled sterile 1.5ml eppendorf 
tubes. The competent E. coli cells were flash-frozen in liquid nitrogen and stored at 
-80�C. 
2. 2. 1. 3 Heat-shock transformation of plasmid DNA or ligation products into 
competent E. coli cells 
Frozen competent E. coli cells were thawed on ice until the suspension has just 
liquefied. Plasmid DNA or ligation product to be transformed was added to each 
aliquot of competent cells in a volume of less than 20|il. The tubes were finger-mixed 
gently and placed on ice for 60 minutes. Heat-shock transformation was performed by 
41 
Materials A nd Methods 
placing the tubes into a 42°C water bath for 90 seconds and returning them 
immediately on ice for 2 minutes. 0.8ml SOC medium was added to each tube. The 
transformed E. coli were recovered by incubating at 37�C for 60 minutes with shaking 
at 250 rpm. The recovered cells were then spread onto LBAp agar plates and 
incubated at 37°C for 16-18 hours. Bacterial colonies formed were picked and 
screened for the presence of recombinant plasmid by restriction mapping analysis. 
2. 2. 1. 4 Transformation of ligation products into electrocompetent E. coli 
ElectroMax DHIOB™ (GibcoBRL,Gaithersburg,M. D.) by 
electroporation 
One aliquot of ElectroMax™ DHIOB E. coli was thawed on ice, and 20^1 of it 
was transferred into a pre-chilled sterile 1.5ml eppendorf tube. The ligation product to 
be transformed was added to the Kcoli cells and kept on ice for at least 15 minutes. A 
sterile disposable Electroporation Cuvette Plus™ cuvette with a 2mm gap (BTX, Inc.) 
was also chilled on ice for at least 15 minutes. The cuvette, with the DNA-E. coli 
mixture, was placed into the pulse chamber of the EasyJect™ electroporator 
(EquiBio™). A single pulse at 2500V with impedance set at 25Q was delivered for a 
period of less than five milliseconds. The electroporated cells were transferred to a 
sterile 1.5ml eppendorf tube and allowed to recover in SOC medium as in the case of 
heat-shock transformation. Cells were spread onto LBAp agar plates and incubated at 
37�C for 16-18 hours. Bacterial colonies were picked and screened for the presence of 
recombinant plasmid by restriction mapping analysis. 
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2. 2. 1. 5 MiniPrep of plasmid DNA by phenol-chloroform extraction method 
(modified from Sambrook et al.，1989) 
Single colonies were first streaked onto a fresh LBAp agar plate as replica 
before inoculating into LBAp medium at 2ml/colony. The replica plate was incubated 
at 3TC for 16-18 hours, while the inocula were incubated at 37°C for 16-18 hours 
with shaking at 250 rpm. 1.5ml of each bacterial suspension was harvested separately 
by centrifuging at 13,000 rpm at 4°C for 90 seconds. Each bacterial pellet was 
resuspended in 100|il ice-cold Solution I and kept on ice for five minutes. Two 
hundred microlitres freshly prepared Solution II at room temperature were then added. 
After mixing gently for 5 seconds, the bacterial lysate was kept on ice for 5 minutes. 
One hundred and fifty microlitres pre-chilled Solution III was added and the mixture 
was kept on ice for five minutes after vigorous vortexing. The neutralized lysate was 
centrifliged at 13,000 rpm at 4°C for 10 minutes. The supernatant was saved in a 
sterile 1.5ml eppendorf tube and an equal volume of phenol/chloroform was added. 
The mixture was mixed vigorously and centrifliged at 13,000 rpm at 4°C for two 
minutes. The supernatant, with plasmid DNA extracted, was saved. Plasmid DNA 
was precipitated by adding one volume of absolute isopropanol at room temperature 
and centrifuging at 13,000 rpm at 4°C for 30 minutes. The DNA pellet was saved and 
the residual amount of isopropanol was removed by dying in a Speed Vac (FTS 
Systems) for 15 minutes. The purified plasmid DNA was resuspended in 40^1 TE 
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buffer with 10|il RNase A (20|ag/ml) and incubated at 37°C for three hours or 4°C 
overnight to remove any RNA present. 
2. 2. 1. 6 Large-scale preparation of plasmid DNA using Qiagen* Plasmid Midi 
Kit 
A single colony of bacteria was first streaked onto a fresh LB Amp agar plate 
as replica before inoculating into 25ml LB Amp medium. The replica plate was 
incubated at 37°C for 16-18 hours, while the inoculum was incubated at 37°C for 
16-18 hours with shaking at 250 rpm. Bacterial suspension was harvested by 
centrifuging at 8,000 rpm at 4°C for five minutes. After resuspending in 4ml Buffer 
PI, 4ml Buffer P2 was added to each bacterial pellet and mixed gently. The bacterial 
lysate was incubated at room temperature for five minutes. Four millilitres ice-cold 
Buffer P3 was then added. The lysate was mixed gently and kept on ice for 15 
minutes. The supernatant was saved by centrifuging the lysate at 13,000 rpm for 30 
minutes at 4�C. Meanwhile, a Qiagen-tiplOO was equilibrated with 4ml Buffer QBT 
by gravity flow. The supernatant saved previously was applied onto the Qiagen-tiplOO, 
and the tip was washed twice with 10ml Buffer QC by gravity flow. The bound 
plasmid DNA was eluted with 5ml Buffer QF. The eluent was saved in a sterile 25ml 
polypropylene centrifuge tube (Nalgene) and 0.7 volume of absolute isopropanol at 
room temperature was added. The precipitated DNA was collected by centrifugating 
at 13,000 rpm at 4°C for 30 minutes. The pellet was washed once with 2ml 70% 
ethanol and re-centrifuged at 13,000 rpm at 4°C for 15 minutes. After removing the 
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residual amount of ethanol by freeze-drying, the purified plasmid DNA was 
resuspended in sterile TE buffer and stored at -20°C. 
2. 2.1. 7 Plasmid stocking by keeping transformed E, coli in agar stabs 
Transformed E. coli carrying recombinant plasmid were spread onto a fresh 
LBAp agar plate and incubated at 37°C for 16-18 hours. A single colony of 2-3 mm in 
diameter was picked with a flame-sterilized inoculation loop. The loop was quickly 
stabbed three times into a SOBAp agar stab. The inoculated stab was incubated at 
37°C for 24 hours. The stab was then kept in the dark at room temperature for up to 
two years. 
2. 2. 2 Construction of DBM030-C-HisPfMSP-142 (Secretory^ C-terminal hexa-
His Tagged Transfer Vector 
2. 2. 2 .1 Primer for subcloning Secretory C-HisSp42 
The parent recombinant transfer vector pMbac-PfMSP-l42 containing the 
PfMSP-142 insert (Figure 12) was provided by Prof. George S. N. Hui of the 
Department of Tropical Medicine and Medical Microbiology, University of Hawaii at 
Manoa, Honolulu. 
Custom-made primers were ordered from GibcoBRL. A forward primer specific to 
the melittin signal peptide sequence of transfer vector pMbac (42k-F- SmaIN) was 
designed and the sequence is as follows: 
Smal 
5’ TAG GCC CCC GGG ATG AAA TTC TTA GTC AAC GTT GCC 3’ 
An end clamp of six nucleotides (TAGGCC) was introduced into the 5' 
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Figure 12. Restriction map of transfer vector pMbac (upper) and the honeybee 
melittin signal peptide sequence downstream of the polh promoter (lower). The 
cleavage site of the signal peptide is indicated by the arrow. PfMSP-142 (underlined) 
was cloned into the Sma\ site beforehand. (Map of pMbac adopted from Lopez-Ferber 
etal, 1995) 
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position of the primer to facilitate docking of restriction enzyme onto the PCR 
product for digestion. A Smal site (underlined) was included following the end clamp. 
For construction of 6xHis Taggeed Secretory PfMSP-142, a reverse primer specific to 
the 3’ end of PfMSP-142 with six histidine codons was made as follows: 
5' TAG GAT CGT CTA GA|T TA|G TGG TGG TGG TGG TGG TGG TGG GAA 
Xbal 6x his 
CTG CTGAAAATACS' 
A contiguous hexapeptide of histidine to the 3，position of PfMSP-142 with a stop 
codon was introduced (TAA). Xbal restriction site (underlined) was introduced into 3， 
end ofPfMSP-142. 
2. 2. 2. 2 Amplification of Secretory C-HisPfMSP-142 (C-HisSp42) by PWO DNA 
Polymerase 
PCR was performed to amplify the C-HisSp42 construct using the two primers 
mentioned above. The reactions were carried out in a PTC-IOOtm Programmable 
Thermal Controller (MJ Research, Inc.). For the sp42 construct, in each reaction, 
2mM dNTP, 5^1 lOx POWVCK buffer，6^ 1 of forward (lOOng/nl) and 7.5^1 reverse 
primers (76ng/nl), l|il pMbac-p42 (260ng/^il) and 2.5 units oiPWO DNA polymerase 
(Roche) were added and the mixture was made up to SO i^l with sterile ddHzO. PCR 
was started by a five-minute incubation at 94�C followed by 30 cycles of incubation 
as follows: 95°C for 36 seconds, 58°C for one minute, 72°C for three minutes. The 
reaction was stopped after a further incubation at 72°C for ten minutes. The PCR 
product was purified by the GeneClean® method mentioned previously. 
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2. 2. 2. 3 Preparation of pBM030/500NcoI vector 
The transfer vector pBM030 was a gift from Prof. Susuma Maeda of the 
Department of Entomology, University of California, Davis (Figure 13). A stuffer 
fragment was introduced into the Ncol restriction site in pBM030 for the purpose of 
confirming restriction digestion. The modified plasmid was transformed into DH5a. 
To prepare the vector for the cloning of the PMSP-I42 insert, 2ml DH5a bacterial 
culture was grown overnight and was taken for plasmid extraction (Midipreps 
Promega). 5|ig pBM030/500NcoI vector was cut by Smal (8.25 units) and Xbal (6.75 
units) (Pharmacia Biotech) in Ix OPA+ buffer in a reaction volume of 30^1 at 37°C 
overnight. After GeneClean®, the vector was stored at -20�C and ready for ligation 
with the insert. 
2. 2. 2. 4 Restriction of PCR products for cloning into pBM030/500A^coI transfer 
vector 
The PCR product of sp42 was digested with ten units each of Smal and Xbal 
(Pharmacia Biotech) in Ix OPA+ buffer in a reaction volume of 50|il at 37�C 
overnight. The restricted product was purified by GeneClean®. 
2. 2. 2. 5 Cloning ofC-HisSp42 into pBM030/500A^coI 
Smal and Xbal digested pBM030/500A^coI was ligated with the C-HisSp42 
insert containing compatible ends in a mass ratio of 1:5 (53.4ng:245.89ng). For each 
reaction, one unit of T4 DNA ligase (GibcoBRL) was used in Ix ligation buffer. 
Sterile ddHzO was added to make up the reaction volume to 20|il. Ligation was 
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Figure 13. Restriction map of transfer vector pBM030 (upper) and the flanking 
sequence of the multiple cloning site (lower). The Hindlll site at position 8700 is 
absent when comparing to that in Horiuchi et al (1987) and is confirmed by 
restriction mapping analysis in the present study. Shaded regions represent the 
flanking sequences of the viral polh gene required for homologous recombination. 
(Adopted from O'Reilly et al, 1994) 
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carried out at 16°C for overnight. Two volumes of absolute ethanol were added to the 
reaction mixture and it was kept on ice for 15 minutes to precipitate DNA. The 
ethanol was removed after centrifuging at 13,000 rpm at 4°C for 30 minutes. The 
DNA pellet was air-dried and resuspended in 20|il sterile ddHzO before 
electroporating into electrocompetent E. coli ElectroMax DHIOBtm (GibcoBRL). The 
overall strategy for construction of pBM030/C-HisSp42 is illustrated in Figure 14. 
2. 2. 3 Construction of N-terminal hexa-histidine Transfer Vector (pBM030/ 
N-HisSp42) for FVO and 3D7 strains 
2. 2. 3. 1 Primers designed for FVO and 3D7 strain N-terminal 6x His tagged 
Secretory-PlMSP-l42 
Custom-made primers were designed for construction of Secretory N-terminal 
6x His tagged PfMSP-U� of two different strains of Plasmodium Falciparum (FVO 
and 3D7). For the FVO construct, the forward primer was as follows: 
5' C CAC CAC CAC CAC CAC CAC GCA GTA ACT CCT TCC GTA ATT G 3， 
Six histidine residues (underlined) were incorporated at the 3，end of Sp42 
sequence following the signal peptide sequence. As blunt end ligation was carried out, 
no restriction site was introduced. The reverse primer was designed to prime the 3' 
end of FVO PfMSP-Ui as indicated: 
5' TAG GCC GTCTAGATT AGG AAC TGC AGA AAA TAC 3， 
KXbal site was introduced at the 3’ end for sticky end ligation. For the 3D7 
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5' C CAC CAC CAC CAC CAC CAC GCA ATA TCT GTC ACA ATG GAT AAT 
ATC3' 
5' TAG GCC CCT CTA GAT TAG GAA CTG CAG AAA ATA 3' 
2. 2. 3. 2 Restriction of pBM030/ PfMSP-l42 for cloning of FVO and 3D7 strains 
sp42 
pBM030/PfMSP-142 was used as the vector backbone for construction of the 
FVO and 3D7 transfer vectors. pBM030/PfMSP-l42was first restricted by Ncol 
restriction enzyme and then the 5' protruding end was removed by Mung Bean 
nuclease treatment. The PfMSP-142 fragment was then released by Xbal cut. After 
GeneClean®, the vector with a blunt end and a sticky end was ready for ligation with 
the insert prepared by PCR (Figure 15). 
2. 2. 3. 3 Cloning of amplified FVO and 3D7 strains N-HisSp42 into pBM030 
with signal peptide sequence 
Two N-terminal 6x histidines tagged p42 sequences were amplified from their 
pMbac (provided by Prof. George S. N. Hui) containing vector by PCR. The PCR 
amplified products were cut by Xbal. After GeneClean the inserts were ligated with 
the pBM030 pre-cut vector which contained the signal peptide sequence. The overall 
strategy in construction of pBM03 0/N-HisSp42 of FVO and 3D7 strains is as 
illustrated in Figure 15. 
2. 2. 4 Virus Works 
2. 2. 4 .1 BmN cells 
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silkworms Bombyx mori. It was a gift from Prof. Susumu Maeda of the Department of 
Entomology, University of California, Davis. BmN cells were cultured in complete 
insect cell culture medium in 75cm^ culture flasks or 100mm culture dishes (both 
from Corning®, Corning, N. Y.) at ITC. Cells were subcultured by scraping them off 
with a sterilized rubber policeman every three days or before 100% confluence. 
2. 2. 4. 2 Bombyx mori Nuclear Polyhedrosis Virus (BmNPV) 
Wild-type (wt) BmNPV (T3 isolate) was also a gift from Prof. Susumu Maeda 
of the Department of Entomology, University of California, Davis. The virus was 
propagated and amplified by in vitro infection of BmN cells. The culture medium of 
infected BmN cells was saved as viral stock and was stored at 4°C. 
2. 2. 4. 3 Rearing of silkworms 
Silkworms were provided by Dr. Z. Q. Meng of the Zhejiang Academy of 
Agricultural Sciences, Hangzhou. They were cultivated in spacious plastic trays at 
27°C and fed with fresh mulberry leaves (Appendix 1) or artificial diet from 
Hangzhou. 
2. 2. 4. 4 Infection of BmN cells with wild-type or recombinant BmNPV 
BmN cells growing in log phase (1-2x10^ cells/ml) were seeded to culture dishes 
the day before infection (at 1.8x10^ cells for each 60mm dish and 5.5x10^ cells for 
each 100mm dish) and incubated at 2TC overnight. Before infection, the complete 
insect cell culture medium was discarded and replaced with a minimal volume of the 
infection medium. An appropriate volume of virus was inoculated. The infection 
process was carried out at room temperature for one hour with gentle and even 
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rocking of the culture dishes at 15-minute intervals. Three millilitres (for 60mm dish) 
or 8ml (for 100mm dish) of complete insect cell culture medium was then added and 
the infected cells were further incubated at 27°C until harvest. 
2. 2. 4. 5 Infection of silkworms with wild-type (wt) or recombinant BmNPV and 
extraction of hemolymph (Choudary et aL, 1995) 
Silkworms at early fifth instar (one to three days after molting, body weight 
between 2.5 to 4.0g) were used for infection. Larvae were starved for three hours 
before viral infection. At the same time, wt or recombinant BmNPV was diluted 
ten-fold in Grace's insect cell culture medium supplemented with Ix PSF to �l .SxlO^ 
pfu/|il. Silkworms were anesthetized on ice for 20 minutes and then gently cleaned 
with 70% ethanol. Twenty microlitres of the diluted virus was injected longitudinally 
underneath the dorsal cuticle of each larva by a 1/2 c.c. Ultra-Fine® II short needle 
insulin syringe (Becton Dickinson). Infected silkworms were fed as usual at room 
temperature until symptoms of severe viral infection were observed (e.g. cessation of 
food consumption and movement, yellow cuticles, and softened body texture). To 
collect the hemolymph, prolegs of the silkworms were cut with scissors and 
hemolymph was allowed to drain into a sterile 1.5ml eppendorf tube. Dithiothreitol 
(DTT) was immediately added to a final concentration of 5-lOmM to prevent 
melanization. The hemolymph was kept at 4°C for occlusion body extraction or 
flash-frozen in liquid nitrogen and then stored at -80°C for recombinant PfMSP-142 
protein purification. 
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2. 2. 4. 6 Isolation of occlusion bodies and extraction of wild-type BmNPV 
particles (Maeda, 1989) 
Ten millilitres of the wt BmNPV-infected hemolymph was centrifuged at 
room temperature at 3,500rpm for ten minutes. The supernatant with oily debris was 
removed carefully. The pellet containing occlusion bodies was resuspended in 4ml 
occlusion body lysis buffer. The lysis mixture was mixed gently and kept on ice for 30 
minutes. After that, it was centrifuged at 3,500 rpm at room temperature for ten 
minutes. The supernatant with the released wt BmNPV particles was saved. The pellet 
was subjected to another round of lysis to extract virus particles from any unlysed 
occlusion bodies. The supernatants were pooled and stored at 4°C for subsequent 
extraction of viral genomic DNA. 
2. 2. 4. 7 Purification of wild-type BmNPV genomic DNA 
Two millilitres of the extracted BmNPV particles were layered onto 1ml 40% 
(w/v) sucrose cushion in a 4.5ml-polyallomer ultracentrifuge tube (Beckman) and 
centrifuged at 30,000 rpm at 15°C for one hour. The viral pellet was saved and 
resuspended in 400^1 TE buffer. 0.05 volume of Proteinase K (Sigma, St. Louis, MO) 
at 20mg/ml and 0.1 volume of 10% (w/v) SDS solution were added to lyse the viral 
coat proteins at 55°C for one hour. One volume of phenol/chloroform was then added 
to extract the viral genomic DNA by mixing the content back-and-forth slowly ten 
times. The mixture was centrifuged at 13,000 rpm at 4°C for five minutes and the 
aqueous upper layer containing the viral DNA was saved. The extraction process was 
repeated twice with phenol/chloroform and two more times with chloroform alone. 
56 
Materials A nd Methods 
The organic layers were pooled and back-extracted by adding 100-200^1 TE buffer 
and re-centrifuged at 13,000 rpm at 4°C for five minutes. The aqueous layers were 
pooled. The integrity of the purified viral DNA was checked by agarose gel 
electrophoresis (Figure 16). The DNA preparation was stored at 4�C. 
2. 2. 4. 8 Transfection of wt BmNPV genomic DNA into BmN cells by lipofusion 
Two micrograms BmNPV DNA were made up to 300^1 with Grace's insect cell 
culture medium (solution A) just before transfection. Meanwhile, of 
LipofectAMINE™ reagent (2mg/ml) from GibcoBRL (Gaithersburg, M. D.) were 
made up to 300^1 with Grace's insect cell culture medium (solution B), also just 
before transfection. Solution B was slowly added to solution A, and the mixture was 
incubated at room temperature for one hour to form a DNA-liposome complex. 2.4ml 
Grace's insect cell culture medium was then slowly added to the DNA-liposome 
mixture. BmN cells in log phase were seeded to 60mm dishes to 60% confluence the 
day before transfection; and they were washed twice with Grace's insect cell culture 
medium before the experiment. The DNA-liposome mixture was gently applied to the 
BmN cells, and transfection was allowed to proceed at 2TC for 5 hours. Three 
millilitres of recovery culture medium (Grace's insect cell medium with 20% HIFBS) 
was added to stop the transfection process. The transfected BmN cells were further 
incubated at 27�C for 19 hours. The medium was then replaced with 3 ml complete 
insect cell culture medium and incubated at 2TC for six days. The success of the 
transfection process was confirmed by the presence of occlusion bodies. 
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1 2 
I 
Figure 16. Examination of the integrity of purified wt BmNPV genomic DNA. Lane 1: 
purified wt BmNPV genomic DNA. Lane 2: GeneRulerTM DNA Ladder Mix (0.3|ag 
total DNA) (Amersham Pharmacia Biotech). Owing to the large genome size 
(�130kbp), the viral genomic DNA was retained in the sample well. DNA bands of 
lower MW were probably fragments of viral DNA. Electrophoresis was performed 
using a 0.8% (w/v) agarose gel. 
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2. 2. 4. 9 Cotransfection of wt BmNPV genomic DNA with recombinant pBM030 
transfer vector into BmN cells to generate recombinant BmNPV 
The procedure was the same as described for the transfection of wt BmNPV DNA, 
except 4\ig recombinant transfer vector were added to Solution A. On day 6，the 
culture medium was harvested with cell debris removed by centrifugation at room 
temperature at 3,500rpm for ten minutes. This transfection stock was stored at 4° C 
and used to generate the first progeny of the recombinant viral stock. 
2. 2. 4.10 Viral titer determination 
Serially diluted viral stock was used to infect BmN cells. After infection, the 
viral inoculum was aspirated and agarose medium was overlaid onto the cells. The 
agarose medium was allowed to set at room temperature for 20 minutes. Afterwards, 
the dishes were wrapped with parafilm (American National Can™) and incubated 
upside down at 27°C for six days. On day 7，1ml Neutral red-agarose medium was 
overlaid onto the agarose medium and the cells were further incubated at 27°C for 24 
hours. The translucent viral plaques were visualized against a red-colored background 
and counted. Pfu was calculated according to the following equation: 
pfu/ml = number of plaques x (1/ dilution factor) 
2. 2. 5 Purification of Recombinant BmNPV Carrying Different PfMSP-U? 
Constructs 
2. 2. 5 .1 Plaque assay with viral plaque lifting 
The transfection stock serially diluted to 10"^  - 10'^  fold in infection medium 
was used to infect BmN cells seeded in 60mm dishes at 1.8x10^ cells/dish. 
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Mock-infected control was also performed. The volume of infection inoculum was 1 
ml/dish. Agarose medium was overlaid onto the BmN cells as mentioned in section 2. 
2. 4. 10. On day 6，the agarose overlays were gently pliered out and each of them was 
transferred to a larger sterile culture dish with the cell-side facing upward. A piece of 
autoclaved 0.45nm pore-size ZetaProbe® membrane (Bio-Rad) cut to 60mm in 
diameter was gently put onto each overlay. The membranes were allowed to soak for 
five minutes. A 23-G needle (Terumo) dipped in sterile black ink was used to pierce 
the membrane with the agarose overlay at three asymmetric positions. The 
membranes were then lifted with forceps and dried at room temperature for 15 
minutes with the agarose-side up. The membrane was blocked in 15ml PBSTM 
(blocking buffer) for 30 minutes and then changed to fresh PBST with the addition of 
20ng first antibody (mAb5.2 monoclonal antibody). The rest of the procedures were 
done as described in western blot method (section 2. 2. 8. 5). 
2. 2. 5. 2 Plaque picking 
Signals detected on the developed membrane were used to locate the positions 
of recombinant viral plaques on the agarose overlays. A sterile PI000 pipette tip 
connected to a rubber bulb was used to penetrate the agarose to suck up the cell 
monolayer containing the recombinant plaque. Agarose plugs collected in this way 
were each resuspended in 200|j.l infection medium at room temperature overnight to 
release the immobilized viruses. The viral suspension can then be use for infection of 
BmN cells for further round of purification of recombinant BmNPV. 
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2. 2. 5. 3 ELISA screening for purification of recombinant BmNPV 
BmN cells was seeded to ten 96 wells plates at a concentration of 2.048 x lO* 
cells/well one day before infection with the recombinant virus cotransfection stock. 
The virus stock was diluted to yield 1-10 pfu per well. lOO i^l diluted virus was used to 
infect overnight culture of BmN cells grown in each well of a 96 wells plate. 
Mock-infected positive and negative controls were also performed. The volume of 
culture medium was adjusted to 200nl/well. On day 5, 80|il infected culture medium 
from each well of the ten 96 wells plates was transferred to ELISA plates (Nalge 
Nunc International), which had been coated with mAb5.2 monoclonal antibody. 
Preparation of mAb5.2 coated ELISA plate was as described in section 2. 2. 9. 1. The 
subsequent assay of sp42 expression was the same as the procedures used in sandwich 
ELISA. To handle the large number of plates, an Automated Workstation 
Biomark2000 (Beckman) was used (The program designed for this procedure is 
described Appendix 2). The ten 96 wells culture plates containing the infected culture 
medium were stored at 4°C during the assay. 
2. 2. 6 Expression of Recombinant C-HisPfMSP-ld? Protein 
2. 2. 6 .1 In vitro expression in BmN cell culture 
5 X 10^ BmN cells in log phase were seeded to a 100mm culture dish on the 
day before infection. The cells were infected with recombinant BmNPV at a 
multiplicity of infection (MOI) of one. The infection process was performed as 
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mentioned in section 2. 2. 4. 4. Infected BmN cells and culture media were harvested 
four days post-infection (d.p.i.). Cell and debris were pelleted by centrifugation at 
3000rpm for 5 minutes at room temperature. The supernatant was collected to assay 
for the presence of C-HisPfMSP-l42. Expression of recombinant protein was 
characterized by SDS-PAGE and Western blot. Crude culture medium was loaded to 
the gel directly after treatment with SDS-PAGE loading buffer. 
2. 2. 6. 2 In vivo expression in silkworms 
Silkworms were individually infected with recombinant virus according to the 
method mentioned in section 2. 2. 4. 5. Hemolymph samples were harvested from 
three silkworms each day after infection for six to seven days. The expression of 
recombinant C-HisPfMSP-l42 proteins was characterized by sandwich ELISA, 
SDS-PAGE, and Western blot. 
2. 2. 7 Purification of recombinant C-HisPfMSP-lj? protein bv Nickel ion 
charged Chelating Senharose Fast Flow column (IMAC) (Pharmacia 
Biotech) 
2. 2. 7. 1 Preparation of Chelating Sepharose Fast Flow column by charging the 
gel with Nickel ion (Ni:.) 
All buffers used were first filtered through 0.45 jim pore-size membrane filters. 
Chelating Sepharose Fast Flow gel is supplied in 20% ethanol. 6ml gel was 
transferred to a 15ml Falcon tube and it was washed with 2 bed-volumes of dHiO 
three times. Then the gel was charged with nickel ion by adding 0.5 gel volume of 
0. IM NiS04 solution. The charging matrix was incubated at room temperature for 5 
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minutes with end-over-end rotation. The charged gel was sedimented by centrifuging 
at l,500rpm for 2 minutes. The supernatant was decanted and the gel was further 
washed with two gel-volumes of dHzO three times. The charged gel was equilibrated 
by washing with two bed-volumes of Start buffer for three times and stored at 4 � C 
until ready for hemolymph binding in IMAC purification. 
2. 2. 7. 2 Purification of recombinant C-HisPIMSP-l42 protein by Nickel ion 
charged chelating Sepharose Fast Flow column. 
2.5ml hemolymph sample was centrifuged at 13,000rpm at 4°C for 15 minutes. 
The supernatant containing C-HisPfMSP-l42 protein was collected and was diluted 
three fold with Start buffer (20mM NazHPO*，2M NaCl, pH8.2). The reducing agent, 
DTT, was removed from the hemolymph sample by dialysis against 2L Start buffer 
with a 3000-8000 NMWL dialysis tubing at 4 � C overnight. The dialyzed hemolymph 
sample was mixed with 7ml charged chelating matrix in a 15ml Falcon tube. The 
mixture was gently shaked until fully-resuspended and it was incubated at 4°C for 3 
hours with end-over-end rotation. Afterwards, the slurry mixture was packed into a 
glass Econo-Column chromatography column (10mm x 100mm, Bio-Rad). The flow 
through was reloaded three times in order to recover gel adhered to the wall of the 
Falcon tube. The eluent of the final pass was saved as flow through (ft). The column 
was then washed with 20 bed-volumes of Start buffer and the first 2 bed-volumes of 
eluent were saved separately as (stwl) and (stw2). The last bed-volume of eluent was 
also saved (stwf) for checking any contaminant present later. The second and third 
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round of washing were done the same way as the first except the buffer was changed 
to first wash buffer (lOmM imidazole in Start buffer, pH8) and second wash buffer 
(50mM imidazole in Start buffer，pH 6). In each washing, ten one-bed volume 
fractions were collected. Elution of absorbed materials by elution buffer (0.4M 
imidazole in Start buffer, pH5.5)was carried out in a total of eight one bed-volume 
fractions. All the fractions collected were stored at 4°C. The column was regenerated 
by washing with 3 bed-volume of regeneration buffer (0.05M EDTA, 0.5M NaCl). 
Once the chelating gel was uncharged, it will return from the charged light blue color 
to the original white gel color. The column was reconditioned for future used by 
washing with three bed-volumes of dHaO three times followed by the same volumes 
of 20% ethanol (reagent grade). Chelating gel resuspended in 20% ethanol was 
transferred to a 15ml Falcon tube and stored at 4°C. In all of the above steps, the 
column was eluted by gravitation flow. 
2. 2. 8 Protein Analysis 
2. 2. 8. 1 Protein separation by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out according to Laemmli (1970). Resolving and 
stacking gels were prepared and casted in the Mini-PROTEAN® II electrophoresis cell 
(Bio-Rad). Each protein sample was mixed with an equal volume of 2x loading buffer 
and heated at 95°C for five minutes. Samples were then centrifuged at room 
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temperature at 13,000 rpm for five minutes. The clarified supernatants were loaded 
and the gels were run at 30mA/gel. 
2. 2. 8. 2 Coomassie Brilliant Blue R-250 staining of SDS gels 
Gels were stained in SDS-PAGE staining solution at room temperature 
overnight with gentle shaking. The gels were then destained in destaining solution at 
55°C with gentle shaking until the background was removed. After rinsing with tap 
water, the gels were dried under vacuum. 
2. 2. 8. 3 Silver staining of SDS gels by Silver Stain Plus kit (Bio-Rad, Hercules, 
CA) 
Each piece of resolving gel was fixed in 50ml fixative enhancer solution for 
20 minutes at room temperature with gentle shaking. The gel was then rinsed at room 
temperature for 20 minutes in 100ml dcffl^O with three changes of ddHzO. Freshly 
prepared staining substrate solution was added and the gel was stained at room 
temperature for about 15 minutes with gentle shaking. The gel was finally fixed in 
50ml 5% (v/v) glacial acetic acid at room temperature for 20 minutes and rinsed 
thoroughly in dHzO before vacuum drying. 
2. 2. 8. 4 Protein transfer using Mini Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad) 
The process is also called "Wet Transfer". The resolving gel was equilibrated 
in chilled Bjerrum and Schafer-Nielsen transfer buffer for 15-30 minutes. A piece of 
0.2|im pore-size PVDF membrane (Bio-Rad, Hercules, CA) cut to the size of the gel 
was activated in reagent grade methanol and then equilibrated in transfer buffer for 15 
minutes. A stack of Whatman® 3MM Chr Chromatography paper cut to the size of the 
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gel was also soaked in the transfer buffer. The electrophoretic transfer cell was set up 
as illustrated in the instruction manual. Proteins were transferred from the gel to the 
PVDF membrane at lOOV for one hour. After the transfer, the membrane was ready 
for Western blotting. The efficiency of protein transfer was checked by staining the 
transferred gel with Coomassie Brilliant Blue R-250. 
2. 2. 8. 5 Western blotting 
Each membrane was blocked in 15ml blocking buffer at room temperature for 
one hour. The blocking solution was changed and 20|ig of monoclonal antibody 
mAb5.2 was added. Probing of antigen was carried out at room temperature for one 
hour or at 4°C overnight with gentle shaking. The membrane was then washed three 
times (ten minutes each) in 25ml pre-chilled wash buffer. Afterwards, 15ml blocking 
buffer was added with 3|il EIA-Grade affinity purified goat-anti-mouse IgG (H+L) 
AP conjugate (Bio-Rad, Hercules, CA). The membrane was incubated at room 
temperature with gentle shaking for one hour and it was washed again as mentioned 
before. Finally, after rinsing the membrane with 2ml AP substrate buffer, the AP 
substrate solution was added. Color development was carried out in the dark at room 
temperature for 20 minutes and was stopped by flushing the membrane under tap 
water for two minutes. The membrane was then air-dried and kept away from strong 
light. 
2. 2. 8. 6 Protein content determination by Protein Assay Kit (Bio-Rad, Hercules, 
CA) 
The working dye reagent was prepared by diluting one part of the Dye 
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Reagent Concentrate with four parts of ddHaO. Twenty microlitres of protein sample 
or protein standard was mixed with 1ml of the working dye reagent. The mixture was 
incubated at room temperature for 15 minutes. Bovine serum albumin (BSA; Fraction 
V, Sigma, St. Louis, MO) was used as protein standard. Optical density at 595nm 
(OD595) was measured either by a spectrophotometer, with the sample loaded into a 
disposable cuvette (Sarstedt), or by a microplate reader, with the samples loaded into 
framed PolySorp polystyrene Nunc-Immuno® Modules (Nunc InterMed). 
2. 2. 9 ELISA 
2. 2. 9 .1 Sandwich ELISA 
MAb5.2 diluted in ELISA coupling buffer (0.5|ig/ml; 100|il/well) was coated 
onto 96-well MaxiSorp polystyrene plates (Nalge Nunc International) at 4°C for 
16-24 hours. The plates were flicker-dried and washed three times (five minutes each) 
with 200|j,l/well of blocking buffer. Sites on the plates were then saturated with 
200|il/well of saturation buffer at room temperature for one hour. After saturation, the 
plates were flicker-dried and washed three times (five minutes each) with 200|il/well 
of wash buffer. After the plates were flicker-dried samples and standards were loaded 
onto the plate at 100|il/well. Antigen capture was carried out at room temperature for 
one hour. Afterwards, the plates were flicker-dried and washed three times (five 
minutes each) with 200|^l/well of wash buffer. Rabbit antiserum against recombinant 
PfMSP-142 protein was diluted 128,000-fold in saturation buffer and pipetted into the 
plates at lOO^il/well. The plates were incubated at room temperature for one hour. 
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Afterward, the plates were then flicker-dried and washed five times (five minutes 
each) with 200^il/well of blocking buffer. EIA-grade affinity purified goat-anti-rabbit 
IgG (H+L) HRP-conjugate (Bio-Rad, Hercules, CA) was diluted 2000-fold in 
secondary antibody buffer and pipetted into the wells at lOOnl/well. The plates were 
then incubated at room temperature for one hour. Finally, the plates were flicker-dried 
and washed three times (five minutes each) with blocking buffer and then twice (five 
minutes each) with wash buffer, at 200^1/well. The HRP substrate mix was added at 
100|al/well and colour development was performed by incubating the plates at 37°C 
for 20 minutes. Optical density at 405nm (OD405) was measured by a microplate 
reader (Molecular Devices or Bio-Rad). Blanks were included in the plates in which 
all antigens and antibodies were omitted except the respective buffers. 
2. 2. 9. 2 Standardization of Response Curve in Sandwich ELISA 
Since the sandwich ELISA is intended to be used to quantify the expression 
level of recombinant PfMSP-142 protein, mAb5.2 immunoaffinity purified 
recombinant PfMSP-142 was used as a standard for quantitation experiments. Serially 
diluted purified recombinant PfMSP-142 protein was first captured by mAb5.2 coated 
on ELISA plates. lOOjil Rabbit anti-sera diluted to 128,000 fold was then added to the 
plates to determine the amount of antigens captured as described before in the 
sandwich ELISA. The standard (PfMSP-142) serial dilution profile and sandwich 
ELISA signal is shown in Figure 17. The purity of mAb5.2 affinity chromatography 
purified recombinant PfMSP-142 is also shown in the figure and the protein amount 
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estimation of the purified PfMSP-142 was done by protein assay described in section 2. 
2 . 8. 6 . 
2. 2.10 Immunogenicitv Tests 
Five BALB/c mice were immunized with IMAC purified recombinant 
C-HisPfMSP-l42 protein. First immunization was given subcutaneously on the back 
of the mice using a 27g needle. The first immunization injection consisted of 
100ng/300|il recombinant C-HisPfMSP-Ui protein in complete Freund's adjuvant 
(Sigma, St. Louis, MO). The first booster was given two months later and the second 
and third boosters were also given subcutaneously at 14 days intervals. The amount of 
mycobacterium in CFA was successively halved in each of the subsequent 
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CHAPTER 3 CONSTRUCTION AND CHARACTERIZATION OF 
RECOMBINANT BmNPV CARRYING PIMSP-Uz 
The large size of the BmNPV genomic DNA (~130kbp) makes it sensitive to 
minor mechanical damage such as shearing during pipetting. Because of this, direct 
insertion of PfMSP-142 DNA into the viral genome by conventional cloning strategy 
is not possible. In order to insert the PfMSP-142 DNA into BmNPV, an indirect 
cloning method was employed. The PCR product of PfMSP-142 was first cloned into a 
BmNPV-based transfer vector, pBMOSO, to generate the recombinant 
pBM030-PfMSP-l42 transfer vector. Recombinant BmNPVs were then generated by 
cotransfecting BmN cells with the purified BmNPV genomic DNA and the 
recombinant transfer vector. By homologous recombination, the cloned PfMSP-142 
DNA sequence was inserted into the viral genome. A total of three recombinant 
BmNPVs were produced by this method. Two different strains of Plasmodium 
falciparum were used for constructing recombinant BmNPVs. For the 3D7 strain, the 
6x histidine tag was incorporated in the N- (N-HisPfMSP-142 construct) and 
C-terminal (C-HisPfMSP-142 construct) of the PfMSP-142 protein respectively. For the 
FVO strain, the 6x histidine tag was incorporated only in the N-terminal (FVO 
N-HisPfMSP-l42 construct). 
3.1 Clonine of C-HisPfMSP-lii into pBM030 
The progress in the construction of recombinant pBM030/C-HisSp42 transfer 
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vector was monitored by restriction mapping analysis. The PCR products of different 
HisPfMSP-l42 constructs were separately digested with appropriate restriction 
enzyme (Figure 18) and then directionally cloned into the pre-digested transfer vector 
(Figure 19). The identity of the recombinant transfer vector was confirmed by 
restriction mapping analysis (Figure 20) and DNA sequencing of the vector-insert 
junctions (Figure 21). The recombinant transfer vector was subsequently amplified 
and used in the generation of recombinant BmNPVs. 
3. 2 Construction of Recombinant BmNPV Carrying PfMSP-lii 
Before generating recombinant BmNPVs, the purified wt BmNPV genomic DNA 
must be proven to be infectious, i.e. it can generate wt BmNPVs and subsequently, 
occlusion bodies, in BmN cells. In this study, when our viral DNA was transfected 
into BmN cells, occlusion bodies were observed five days after transfection. This 
observation indicates that the viral DNA preparation was infectious and therefore 
suitable for recombinant BmNPV generation. The viral DNA was used to cotransfect 
BmN cells with the recombinant pBM030/C-HisSp42 transfer vector (Figure 21). 
However, because of the low recombination efficiency (around 0.05-2%), most of the 
BmNPVs formed were non-recombinants. Repeated screening and enrichment 
processes were needed to purify the small amount of recombinant viruses. The three 
recombinant BmNPVs described in this thesis were all purified by three to four cycles 
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Figure 21. Sequence context at the junction of the transfer vector pBM030 with the 
C-HisSp42 insert. Black letters are sequencing result and blue letters are p42 
sequence. Cloning sites employed are shown in red (5' Smal CCCGGG and 3' Xbal 
TCTAGA). Flanking vector (pBM030 Figure 13) sequences are underlined and 
corresponding nucleotide positions are denoted by vertical line with a position number. 
Hexa-histidine tag is indicated by green color letters at the 3’ end. 
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Figure 22. Flow-chart of generation of recombinant baculoviruses for heterologous 
protein expression. 1: Construction of recombinant transfer vector. 2: Extraction of 
wild-type viral genomic DNA. 3: Cotransfection of recombinant transfer vector and 
viral genomic DNA into insect cell culture. 4: Plaque assay for isolation of 
recombinant baculoviruses. (Adopted from Page and Rodgers, 1995) 
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3. 3 Punfication of Recombinant BmNPVs 
The ELISA screening method was used to monitor the purification of the 
recombinant BmNPVs. Culture media harvested from the cotransfection was diluted 
to an appropriate concentration to infect BmN cells seeded in 96 wells culture plates 
(Cellstar® Micro-plate with lid, TC, sterile). After a period of incubation (4 days), 
80|aL of the infected culture media (SO i^L) was removed and taken for ELISA 
screening mentioned in section 2. 2. 5. 3. An OD405 (ELISA activity) value more than 
one to two standard deviations above the background was used as an indication for the 
presence of the recombinant virus. Wells with higher ELISA activity would therefore 
indicate a high concentration of recombinant BmNPVs. Positive wells were selected 
for another round of purification. In the next and further round of purification, the loss 
of polyhedrin phenotype in infected cells was monitored and used as a marker for 
selection of recombinant virus. The whole process of infection, amplification and 
ELISA screening was repeated three to four times in order to obtain a final purified 
recombinant virus. Gradual enrichment of positive signals in consecutive rounds of 
screening indicated the success of this ELISA screening method. An example on the 
calculation of enrichment is shown in Figure 23. The recombinant baculoviruses 
generated were respectively named BmNPV-C-HisPfMSP-142 for the C-HisSp42 
construct, BmNP V-N-HisPfMSP-142 for the N-HisSp42 construct and 
BmNPV-N-HisFVO for another strain of Plasmodium falciparum construct. 
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Estimation of ELISA screening method enrichment. 
Formula for calculation of enriched ELISA signal: 
Sample - N I C sample: ELISA activity of purifying clone 
Sp42 - NIC Sp42: BmNPV/PfMSP-142 as +ve reference  
NIC: non-infected control as _ve background signal 
Cotransfected virus 
� 1 • 
0.36-0.1 = 1.084-0.1 = 0.264 
2 1 1 0 4 




~ = 0 958 2.013 -0.585 
4 I 10-^  
2.222 - 0.888 
2.344 - 0.888 
5 I 10-7 
1.159-0.152 
1.109-0.152 而 
Figure 23. Enrichment of ELISA screening method. Gradual increase of ELISA activity 
of purifying clone is observed by comparing with BmNPV/PfMSP-142. After five rounds 
of ELISA screening purification, BmNPV-C-HisPfMSP-142 was used for infect BmN 
cell for 10 day and no occlusion body can be observed. 
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3. 4 In Vitro Expression of Recombinant C-HisPfMSP-ld，protein 
Expression of recombinant protein was confirmed by detecting the presence of 
the protein in BmN cell culture medium after infection. This was done by infection of 
BmN cells with recombinant BmNPV-C-HisPfMSP-Uz at low MOI (MOI= 1). As the 
recombinant C-HisPfMSP-l42 protein could be detected in the culture medium by 
western blot analysis (Figure 24)，the honeybee melittin signal peptide in this 
construct appeared to be correctly processed in BmN cells to generate a secretory 
product. 
3. 5 In Vivo Expression of Recombinant PfMSP-l』，Protein 
The time course of PfMSP-142 expression in silkworms, the in vivo host of 
BmNPV, was examined. 3.4 x pfu of recombinant BmNPV were injected into 
each silkworm to commence the infection process. Over a period of six to seven days, 
the infected silkworms were sacrificed daily and their hemolymph collected for assay 
as shown in Figure 25-26. On the average, about 400|iL hemolymph could be 
harvested from a single silkworm larva. 
The expression profiles of the three recombinant BmNPVs are illustrated in 
Figures 27-29. Similar courses of expression were obtained from the three different 
viruses. PfMSP-Ui could be detected in the silkworm hemolymph four days after 
infection and its expression level dramatically increased from day 5 and reached a 
maxium on day 6. On day 7 the silkworms were, in general, heavily infected and 
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Figure 24. Analysis of in vitro expression of BmNPV-C-HisSp42. Culture media 
from BmN cells infected with BmNPV-C-HisSp42 at MOI = 1 was harvested on 
d.p.i. = 4 and assayed by SDS-PAGE (A) and western blot (B). Different amount 
of culture media were loaded to SDS-PAGE. M: Prestained SDS-PAGE standards, 
low range (BioRad). 
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A 
m m i i 
Figure 25. Photographs showing silkworms having symptoms of viral infection. 
Severe viral infection symptoms are observed in silkworms infected by BmNPV-C-
HisSp42 (A&B). In A clearly showing yellow cuticles when compared with normal 
milk white color in non-infected silkworm (C). 
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Figure 26. Collection of hemolymph from infected silkworm. (A) Infection of the 
silkworm by recombinant BmNPV carrying C-HisPfMSP-142. (B) The prolegs of a 
silkworm were cut and hemolymph was squeezed out. (C) Appearance of hemolymph 
in the course of infection. On d.p.i = 7，most of the muscle of the larva was degraded 
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because of their poor health the level of expression dropped somewhat. At this stage, 
most of the larva would die. The presence of His-PfMSP-l42 protein in 
BmNPV-C-HisPfMSP-l42 infected hemolymph was further confirmed by Western 
blot analysis (Figure 27). A clear signal of the His-PfMSP-Ui protein was 
unequivocally observed. In contrast, there was no prominent increase of the 
corresponding protein band in the silver-stained gel. This was probably due to the fact 
that the recombinant protein only constituted 0.54% of the total hemolymph protein. 
In order to confirm the present of the hexa-histidine residue on the C- or N-terminal 
of each expressed recombinant protein, Western blot analysis with an Anti-6xHis-tag 
monoclonal antibody was carried out along with the PfMSP-142 specific mAb5.2 
monoclonal antibody. The results showed that a western positive band could be 
observed at a similar position indicating that the recombinant protein probably 
contains a his-tag tail. 
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CHAPTER 4 PURIFICATION OF BmNPV-EXPRESSED RECOMBINANT 
C- TERMIAL HEXA-HIS-TAGGED PfMSP-Ui PROTEIN 
In order to purify the recombinant C-HisPfMSP-l42 protein from hemolymph 
of infected silkworms, different elution schemes were tried using both metal chelating 
affinity and other types of chromatography. The chromatographic media used in our 
study included Chelating Sepharose Fast Flow (Pharmacia Biotech), Poros HS/M 
(Cation exchange PE Biosystem) and Superose 6 (Pharmacia Biotech). All buffers 
were filtered by 0.45nm pore-size membrane filtration before use. Insoluble materials 
in the hemolymph were removed by centrifugation at 13,000 rpm at 4°C for 15 
minutes before samples were used for each purification. 
4.1 Nickel ion charged Chelating Sepharose Fast Flow (immobilized metal 
affinity chromatography) 
Various elution conditions were tried to purify C-HisPfMSP-l42 from the 
silkworm hemolymph using IMAC. These conditions included step-gradient of 
decreasing pH, changes in NaCl concentration, increasing step-gradient of imidazole 
concentration or a combination of them. 
4 .1 .1 IMAC with step pH gradient 
Nickel ion charged Chelating Sepharose Fast Flow was prepared as described 
in section 2. 2. 7. Five hundred microlitres of infected hemolymph was diluted 
three-fold in Start buffer (20mM NazHPO*，2M NaCl, pH 8.2) and mixed with 3ml of 
Ni-IDA gel (expected loading capacity of the Ni-IDA chelating gel is 5mg protein per 
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ml gel). Binding of sample was facilitated by incubation at 4°C for Ihour with 
end-over-end rotation of the mixture. The gel slurry was then packed into a 1cm x 
5cm glass column (BioRad). A step-gradient of reducing pH was used to determine 
the best pH condition for elimination of contaminants. After re-loading the 
unabsorbed material for three times, the column was first washed with five 
bed-volumes of Start buffer, pH8.2, followed by further washes with five 
bed-volumes of Start buffer at pH 6 and 5.5 respectively. After the above three rounds 
of washing, absorbed protein was eluted with five bed-volumes of Start buffer, pH 5.0. 
The pH of all the buffers were adjusted by concentrated HCl (37%) and each collected 
fraction equaled one-bed volume of the column. A Centricon® filter unit (Millipore) 
with a MW cutoff of 10,000 was used to concentrate and exchange buffer (dHiO) on 
the selected fractions. The 8-fold concentrated fractions were analyzed by protein 
assay, SDS-PAGE with silver stain and Western blot. As shown in the SDS-PAGE 
result (Figure 30)，the C-HisPfMSP-142 protein (fx. 17) could not be effectively 
purified from all contaminants. High molecular weight proteins (bands with MW > 
lOOKDa) were observed in this fraction as well as some smaller proteins with MW < 
50KDa. The high molecular weight contaminants were unlikely to be aggregates of 
C-HisPfMSP-l42 as they were not positive in Western blot. Base on these results, pH5 
could effectively dissociate the binding between C-HisPfMSP-Ui and Ni-IDA matrix. 




























































































































































































































































































































































































































4.1. 2 IMAC using a step-gradient of increasing concentration of imidazole 
Apart from pH elution, imidazole can also be used to competitively elute the 
binding of histidine residues to the Ni-IDA matrix. Non-specific ionic interactions of 
contaminant proteins with the gel can be reduced by incorporating high salt in the 
elution buffer. 
4.1. 2 .1 IMAC in IM NaCl with step-gradient of increasing imidazole 
concentration 
Five hundred microlitres of hemolymph was three-fold diluted by IM NaCl 
Start buffer. After dialysis against two litres of IM NaCl Start buffer at 4°C overnight 
to remove DDT, 1.5ml of the diluted sample was mixed with 3ml nickel ion charged 
chelating sepharose fast flow gel for binding at 4 � C for 1 hour. The sample-gel 
mixture was packed in a 1cm x 5cm glass column (BioRad). The flow through 
fraction was re-loaded five times to make sure all the materials were absorbed. The 
column was first washed with five bed-volumes of Start buffer and then five 
bed-volumes of Start buffer with lOmM imidazole to eliminate non-specific binding. 
Step-wise increasing concentration of imidazole (20mM - 0.5M, Figure 31) was used 
to elute the C-HisPfMSP-Ui protein. Fractions with volume equaled to one 
bed-volume of the column was collected. The amount of protein in each fraction was 
estimated as described in section 2. 2. 8. 6. Selected fractions were concentrated and 
analyzed by SDS-PAGE and Western blot (Figure 31). In the silver stained 
























































































































































































































































































































with the 0.4M imidazole fractions. In addition, four contaminant bands were also 
observed. Because of this, IM NaCl appears to be ineffective in reducing the 
non-specific ionic interaction between the contaminants and the gel matrix. 
4.1. 2. 2IMAC in 2M NaCl with step-gradient of increasing imidazole 
concentration 
Five hundred microlitres of hemolymph was three-fold diluted with 2M NaCl 
Start buffer and dialyzed against 2 litres 2M NaCl Start buffer at 4°C overnight. 1.5ml 
of the diluted sample was mixed with 3 ml nickel ion charged chelating sepharose fast 
flow gel for binding at 4 � C for 1 hour. The sample-gel mixture was packed into a 1cm 
X 5cm glass column (BioRad). An elution scheme similar to the case of IM NaCl was 
used (section 4. 1. 2. 1). The results are summarized in Figure 32. The amount of 
protein in each fraction was estimated as described in section 2. 2. 8. 6. Selected 
fractions were eight-fold concentrated by ultrafiltration and buffer exchanged with 
dH20 for SDS-PAGE and Western blot analysis. In the silver stained SDS-PAGE gel, 
a major band of C-HisPfMSP-l42 was observed without the presence of contaminating 
bands (fx. 19 in Figure 32). In light of this result, 2M NaCl appears to be an effective 
condition to reduce non-specific ionic interaction between contaminant and the matrix. 
Although purified recombinant C-HisPfMSP-l42 protein can be obtained in this 
purification scheme, a large amount of C-HisPMSP-l42 was lost in the washing step. 
As indicated in the Western blot analysis, nearly half of the total amount of absorbed 




































































































































































































































































































































target to collect the protein of interest at 0.3 and 0.4M imidazole (fx. 17-19). In a 
second experiment (Figure 33a &33b), densitometer tracing was used to determinate 
the pixel intensity of the two elution fractions with the highest degree of purification 
(i.e. fractions 23 &25, see silver stained gel in figure 33b). As shown, 
C-HisPfMSP-l42 was the major band with the highest pixel. According to Western 
blot results, continuous loss of C-HisPfMSP-l42 protein was observed to be associated 
with each of the washing steps from 30mM to 0.2M imidazole. In conclusion, 
significantly C-HisPfMSP-l42 could be obtained using this scheme of IMAC 
purification but unfortunately the yield was low due to losses in the washing steps. 
4.1. 3 IMAC in 2M NaCI with step-gradient of increasing imidazole 
concentration and reducing of pH 
Based on the results obtained in the initial trials of different elution conditions, 
a combination of imidazole and pH elution scheme may be able to provide a better 
resolution in the purification of the recombinant C-HisPfMSP-l42 protein. 2M NaCl 
was used in this and later purification trials as it has been demonstrated to have the 
ability to reduce non-specific binding. In the first experiment, preparation and sample 
binding were done as previously described. After the collection of the flow through 
(fx.O), the column was washed and eluted with a step-gradient of increasing imidazole 
concentration (from 0，0.01, 0.05, 0.1 and 0.4M) and decreasing pH (from 8.24, 6.67, 
6.21, 5.98 to 5.62) as shown in Figure 34. By SDS-PAGE silver staining and Western 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with some major contaminating proteins could be eluted at pH5.98 and O.IM 
imidazole. Additional amount of C-HisPfMSP-142 could also be eluted in a second 
peak with higher purity at pH5.62 and 0.4M imidazole. However, as indicated in the 
silver stained gel, the protein was still contaminated with two high MW and three 
lower MW proteins. The purity of this partly purified C-HisPfMSP-Ui was compared 
with immunoaffinity purified PfMSP-142 (Figure 34 (D)). As indicated, the IMAC 
purified protein was still unsatisfactory when compared to the immunoafFinity 
-purified preparation. In a second set of trial, the washing and elution profile was kept 
the same except 20 bed-volumes of lOmM imidazole wash buffer was used instead of 
10 bed-volumes (Figure 35). After eluting with 10 bed-volumes of the second wash 
(50mM imidazole in Start buffer，pH 6.5), absorbed C-HisPfMSP-l42 was eluted first 
by O.IM imidazole, pH6 followed by 0.4M imidazole, pH5. A significantly purified 
preparation of C-HisPfMSP-142 was obtained in fx.46 (Figure 35). As shown in the 
SDS-PAGE silver stain gel and Western blot analysis, only one contaminant band 
with a MW of 35,000 was observed. Fractions 36-48 were pooled and concentrated by 
a Stirred Ultrafiltration unit (YMIO membrane used) (Amicon® Millipore). The total 
protein content of the concentrated material was determined to be 5.22mg. The purity 
of the final concentrate was examined by SDS-PAGE silver staining as indicated in 
Figure 36. C-HisPfMSP-l42 was found to be the major band and its intensity was 
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20.8 —— 
Figure 36. The SDS-PAGE showing the IMAC purified C-HisPfMSP-142. Partial 
purified C-HisPfMSP-142 was concentrated by Amicon® (Millpore) and 5|ig and 
8.73|ig of total protein were applied. The SDS-PAGE was over stained in order to 
reveal any contaminating protein present in the product. Percentage of protein per 
lane were indicated by red and blue lines respectively. Quantitation of band intensity 
was performed by using Phoretix ID Advance program(Non-Linear Dynamics LTD., 
UK). M: Prestained SDS-PAGE standards, low range (BioRad). 
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purification scheme appears to be effective in purifying of C-HisPfMSP-l42 in single 
IMAC run. 
4.1. 3 .1 IMAC in 2M NaCI and 0.1% NP-40 with step-gradient of imidazole 
concentration and pH 
NP-40 is a mild non-ionic detergent. Contaminating proteins may be dissociated 
from binding to the column matrix or the target protein of interest by treatment with 
low concentrations of this detergent. In this experiment, all buffers used contained 
0.1% NP-40 were used and the elution scheme with imidazole and pH was similar to 
that described in section 4. 1. 3. Two millilitres of hemolymph was applied to the 
column. After washing with lOmM and 50mM imidazole, the absorbed proteins were 
eluted by 0.4M imidazole as shown in Figure 37. By monitoring with sandwich 
ELISA, most of the C-HisPfMSP-l42 protein was eluted in fx.20-22. Selected 
fractions were analyzed by SDS-PAGE and Western blot. From the silver stained gel, 
a lot of contaminants were co-eluted with the C-HisPfMSP-Ui protein (Figure 37 (B), 
fx.20). No improvement of purity was noticed when compared with chromatography 
done without NP-40. 
The above purification scheme was repeated with the modification that NP-40 
was not used in the 50mM imidazole, pH6.14 wash and the final elution buffer (0.4M 
imidazole, pH5.55). Sandwich ELISA was used to monitor the elution profile as 



































































































































































































































































































































































































































































































































































































































































































































PBS at 4°C overnight. The sample was then concentrated by ultrafiltration using a 
centrifugal filter device (Centriplus® Millipore). As indicated in the SDS-PAGE silver 
stained gel, a high MW band and several low MW bands were still present in the 
purified material. In view of these results, NP-40 addition was ineffective in 
improving the purity of C-HisPfMSP-l42 in the IMAC purification. Moreover, the 
prolonged dialysis time needed to remove NP-40 makes this scheme even less 
attractive. 
4. 2 POROS HS/M (Strong Cation Exchanger) 
Perfusion chromatography was tried to purify the C-HisPfMSP-Ui protein 
because it can rapidly separate the target protein from its contaminants in a matter of 
minutes, thus reducing the chance of protein degradation. Five hundred microlitres of 
hemolymph was diluted four-fold with 20mM ammonium acetate, pH4. 2ml of the 
diluted sample was loaded on to a pre-packed 4.6mm x 100mm POROS HS/M 
column (PE Biosystem; bed volume: 1.7ml). After washing with 10 bed-volumes of 
start buffer (20mM ammonium acetate, pH4), 10 bed-volumes of IM NaCl in start 
buffer (pH4.0) was applied for a second wash. The absorbed materials were eluted 
with 2M NaCl in start buffer, pH 8.0 as shown in Figure 39. By sandwich ELISA, a 
large amount of C-HisPfMSP-l42 was lost in the I M NaCl wash and tailing of 
immunoreactivity was observed in the final elution. As indicated in the SDS-PAGE 























































































































































































































































































































C-HisPfMSP-l42 protein (fx.24 &25). In view of this observation, POROS HS/M 
perfiision chromatography was ineffective for purification of C-HisPfMSP-l42. 
4. 3 Combination of chromatographic separations 
Based on the results of our initial trials on IMAC, we decided to combine it 
with other chromatographic methods and see if further purification of 
C-HisPfMSP-l42 could be achieved. 
4. 3 .1 POROS HS/M and IMAC 
POROS HS/M was used as a pre-cleaning step for purification by IMAC. One 
millilitre ofhemolymph was four-fold diluted in the buffer (20mM ammonium acetate, 
pH4.0) and loaded onto a POROS HS/M column. This purification was done as 
described in section 4. 2 and the elution profile is shown in Figure 40 (A). Selected 
fractions (fx.23-25) were taken for further purification by IMAC. Conditions for 
IMAC purification were the same as previously described. As indicated in the 
SDS-PAGE silver stained gel, no further purification could be achieved by IMAC 
when using POROS as a pre-cleaning step. To make matter worse, there seemed to be 
an extensive degradation of the recombinant when using this combined purification 
scheme. 
4. 3. 2 IMAC and Superose 6 size exclusion Separation 
Two millilitres of hemolymph was three-fold diluted with Start buffer (20mM 











































































































































































































































































































































































































































The diluted sample was mixed with 6ml nickel ion charged chelating gel at 4°C for 3 
hours by end-over-end rotation. The slurry was then packed into a 10cm x 1cm glass 
column (BioRad). After the collection of the flow-through (fx.O), the column was 
washed with 120ml Start buffer, 120ml wash buffer containing lOmM imidazole and 
then 10 bed-volumes of wash buffer containing 50mM imidazole. The absorbed 
C-HisPfMSP-l42 protein was eluted by 10 bed-volumes of 0.4M imidazole (Figure 
41a). Fractions 18-24 were pooled and concentrated by Ultrafiltration using a MW 
10,000 cutoff membrane (Millipore). A total of 0.85mg partly purified protein was 
obtained from the concentrate. As indicated in the SDS-PAGE silver stained gel 
(Figure 41b), several major contaminants were still associated with the purified 
product. In an attempt to remove the contaminating protein, 1ml of the pooled 
material was loaded onto a Superose 6 size exclusion column (10cm x 30cm 
Pharmacia). Chromatography was performed in a FPLC system (Pharmacia). The 
column was eluted with a buffer containing 20mM Na2HP04, 2M NaCl and pH8.2 at 
a flow rate of 0.5ml per minute. The elution profile was monitored by absorption at 
280nm (OD280) (Figure 42). Peak fractions were pooled and concentrated separately 
by a Micocon® 10,000 NMWL filter unit (Millipore). Samples were normalized to the 
same amount of protein (5|ig) and were analyzed by SDS-PAGE and Western blot. 
Results from two sets of experiment are shown in Figure 42 (C&D). The strongest 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































silver stained SDS-PAGE, the high MW contaminant was successfully eliminated by 
Superose 6 chromatography but unfortunately several small MW contaminants were 
still associated with this peak. 
In view of the speed of this combined purification scheme and the purity of the 
product obtained, we further evaluate the optimal conditions for purification of 
C-HisPfMSP-l42 using IMAC and Superose 6. IMAC purification was carried out as 
described in section 4. 1. 3 on 2ml hemolymph. In contrast to previous study, IMAC 
was performed at 4°C. The absorbed materials were eluted by 0.4M imidazole, pH5.5. 
Fractions equal to 1/3 bed-volume were collected (fk.20-25; Figure 43A). This 
strategy was adapted to minimize the dilution of the material of interest; i.e. fx.21. 
This fraction in a total volume of 2ml was then taken for chromatography in the 
Superose 6 column as described previously. Pooled fractions at the position of the 
peaks were dialyzed against dHzO (Figure 43B) and concentrated by lyophilization. 
The dried samples were resuspended in 50|il 50mM Na2P04 and analyzed by 
SDS-PAGE silver stain. Peak 3, collected between 35，to 37，(Figure 43B) was found 
to contain the purified C-HisPfMSP-l42 protein with no other contaminating bands 
(Figure 43 C). Compared with the immunoaffinity purified PfMSP-142 standard in lane 
S, materials in peak 3 appeared to be over 90%pure. In view of these observations, 
IMAC followed by Superose 6 chromatography is the best purification scheme to 






























































































































































































































































































































































































































































































































































































































































Characterization Of C-HisP/MSP-]42 
CHAPTER 5 CHARACTERIZATION OF RECOMBINANT C-HISPfMSP-Ui 
PROTEIN 
5.1 Proper formation of disulphide bridges in epidermal growth factor (EGF) 
like domains 
Disulphide bond formation in the M A C purified recombinant 
C-HisPfMSP-l42 protein was examined by resolving the protein in SDS-PAGE under 
reducing (at different concentration of p-mercaptoethanol, P-ME) and non-reducing 
(without P-ME) conditions. As shown in Figure 44, the non-reduced C-HisPfMSP-l42 
protein migrated as a 45kDa polypeptide and its mobility in SDS-PAGE was 
decreased after treatment with increasing concentration of p-ME. The apparent MW 
of the reduced protein increased from 45 to 50kDa as the concentration of P-ME was 
increased from 5 to 50mM. Western blot analysis showed that the ability of mAb5.2 
to react with C-HisPfMSP-l42 protein was dramatically reduced after p - M E treatment. 
This indicates that the disulphide bonds in the protein are essential for interacting with 
the mouse antibody. Similar observations have been made by Chang et al., (1992) and 
Locher and Tarn, (1993). Since mAb5.2 only specifically recognized a conformational 
epitope in non-reduced gpl95 (native merozoite surface protein 1)，it appears that, the 
recombinant C-HisPfMSP-l42 produced in this study is correctly folded and the 
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Characterization Of C-HisP/MSP-]42 
5. 2 Characterization of the integrity of hexa-histidine residues on recombinant 
C~HisPfMSP-l47 protein 
The integrity and the accessibility of the hexa-histidine tag was examined by 
an anti-his monoclonal antibody (Amersham Pharmacia Biotech) in Western bolt 
analysis and ELISA. In Western blot analysis, anti-his antibody was used as the 
primary antibody for binding with the C-HisPfMSP-Ui protein blotted on PVDF 
membrane. As indicated in Figure 44 (Panel C Lane I), no signal could be observed in 
this Western blotting. The masking of the hexa-his residues might have been due to 
the present of a disulphide-dependent conformation at the C-terminal. In support of 
this, when the protein's disulphide bridges were disrupted under reducing condition 
(5mM P-mercaptoethanol treatment), a faintly observable band at MW ~50kDa could 
be obtained in the Western blot. This confirms that the histidine tag was present in the 
recombinant protein but disulphide-dependent conformation may reduce the 
accessibility of the hexa-his tail to the anti-his antibody. 
In order to compare the binding activity of C-HisPfMSP-Uz with mAb5.2 and 
anti-his antibody, both antibodies were coated onto a ELISA (Figure 45) plate, 
respectively. Compared with mAb5.2, extremely low binding of C-HisPfMSP-l42 was 
observed with the anti-his antibody coated plate. This fiirther supports the hypothesis 
that the his-tag tail in the recombinant protein was shielded at the C-terminal. 
5. 3 Immunogenicity of Recombinant C-HisPfMSP-lii Protein 
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Figure 45. Comparison of binding activity of C-HisPfMSP-142 protein with mAb5.2 
and anti-His antibody in ELISA. 50ng/well mAb5.2 and 500ng/well anti-his antibody 
were coated on ELISA plate respectively. Different dilutions of IMAC purified 
C-HisPfMSP-l42 protein were used as the antigen. Anti-Sp42 serum was used to 
quantify the amount of C-HisPfMSP-142 immobilized. HRP-conjugated goat 
anti-rabbit antibody was used for signal development. 
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immunogenicity of the recombinant C-HisPfMSP-Ui protein. BALB/c mouse was 
immunized with the protein in the presence of Freund's adjuvant as described in 
section 2. 2. 10. Since the initial immunization failed and no antibody response could 
be observed, the initial injection result was ignored in this set of experiment. Three 
out of the five mice injected with the antigen died during the course of the experiment. 
Because of this, we were able to continue the study with one. Sera of the mouse were 
collected on day 14，18 and 28 (Figure 46). The titer of the sera against 
immunoaffinity purified recombinant PfMSP-142 was measured by ELISA using a 
rabbit-anti-mouse-IgG-HRP conjugated antibody. An increase of anti-PfMSP-142 titer 
could be observed. By this preliminary result, it appears that the recombinant 
C-HisPfMSP-l42 protein produced in this study could induce an antibody response in 
mouse to recombinant PfMSP-142-
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Figure 46. Preliminary end-point titers of mouse anti-PfMSP-l42 antisera generated by 
immunizing the mouse with recombinant C-HisPfMSP-l42. Mouse was immunized 
with IMAC purified C-HisPfMSP-l42 protein (lOOjag protein per dose in Freund's 
adjuvant). The antiserum titers were assayed at the indicated time point (days post 
first booster injection). The end-point titer was set at OD405 of 0.2. No. of data for 
each time point = 1 mouse. 
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CHAPTER 6 DISCUSSION 
The aim of this study is to produce a vaccine based on the 42kDa 
carboxyl-terminal processing fragment of Plasmodium falciparum Merozoite surface 
protein (PflVISP-Ui) using the Bomhyx mori Nuclear Polyhedrosis Virus (BmNPV) 
expression system in silkworm. Chang et al., (1992) have successfully expressed 
PfMSP-l42 recombinant protein in AcNPV infected Sf9 insect cell culture. There is 
strong evidence indicating that recombinant PfMSP-l42 protein expressed in 
baculovirus could be used as an immunogen to stimulate protection when monkeys 
were challenged with live parasite in vivo (Chang et al., 1996; Stowers et al., 2001). 
However, difficulties in making the antigen reproducibly and the cost of large scale 
production in cell culture have stymied further development. In order to produce a 
baculovirus-expressed form ofPfMSP-l42 in large-scale with lower operating cost, we 
choose to use BmNPV instead of AcNPV in the present study. The advantage of using 
BmNPV is because silkworms, the natural host for this virus, can be used as an 
economical bioreactor to produce the recombinant protein in high yield. 
High level of expression of recombinant PfMSP-l42 has been achieved in our 
laboratory (Pang 2000). In cell culture, a yield of 5.28|ig/ 6x10^ cells could be 
obtained in four days. In silkworm, the level of expression reached 378.86|ig/ml 
hemolymph after seven days of infection. In spite of these encouraging results, we 
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could not find a good scheme to purify the recombinant protein using conventional 
chromatographic techniques. The purpose of the present study is to construct a 
hexa-histidine tagged PfMSP-142 fusion protein to facilitate downstream purification 
by immobilized metal ion affinity chromatography (IMAC). 
6. 1 Construction of recombinant BmNPV carrying HisPfMSP-ljj 
Three recombinant BmNPVs were constructed in this study. Two different 
isolates of Plasmodium falciparum were used for production of recombinant 
PfMSP-142 protein (FVO: Vietnam-Oak Knoll and 3D7). The constructs were all 
designed to secret the target protein using a honeybee melititin signal peptide and 
possess a hexa-histidine tail at either the C- or N-terminus of the two 3D7 constructs 
and at the N-terminus of the FVO construct. It was expected that these strategies 
would help to stabilize expression of the recombinant protein and facilitate 
purification by using IMAC. 
Recombinant BmNPVs were constructed by homologous recombination 
during cotransfection of viral DNA (wtBmNPV) and recombinant transfer vector 
(pBM030/C-HisPfMSP-142) into BmN cell. As the frequency of recombination 
between plasmid transfer vectors and infectious viral DNA is only around 0.1-1.0% 
(Blissard & Rohrmann，1990)，the identification and purification of recombinant virus 
is a tedious exercise. In the previous study, virus plaque assay was used for isolation 
and purification of the recombinant virus. On the average, three to four cycles of 
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purification (including plaque assay, plaque lifting, Southern hybridization and virus 
amplification) were needed to obtain the final recombinant BmNPV. Usually, two to 
three months of work was required before a purified recombinant BmNPV is ready 
for infecting silkworm and in vivo protein expression study. In order to reduce the 
time for virus purification, an ELISA based screening and purification method, as 
described in section 2. 2. 5. 3，was employed in this study. The time for preparation of 
a purified recombinant virus using this modified technique can be shorten to one and a 
half month. As large number of clones are examined in each round of purification, ten 
96 well ELISA plates were used to set up the screening each time. To reduce manual 
labor, we have employed a Biomek® 2000 Laboratory Automation Workstation 
(Beckman) to handle the limiting dilution screen of two to three clones at a time. The 
main advantages of using the ELISA screening are 1) avoid the handling of 
radioactive substance in Southern hybridization; 2) ELISA measures directly the level 
of protein expression. As a result, only recombinant viruses with good level of 
expression were picked. 
6. 2 Expression of recombinant HisPfMSP-lji proteins 
In the present study, we have prepared two recombinant BmNPVs using the 
gene derived from the 3D7 strain and one from the FVO strain. Sandwich ELISA was 
used to quantify the expression level of these viruses and the standard curve for the 
assay was constructed by using the unmodified PfMSP-142 protein purified by 
123 
Discussion 
immunoaffinity chromatography. Base on this reference curve, we were able to 
quantify the expression level accurately. The sandwich ELISA used was sensitive 
enough to detect as little as a few nanograms of PfMSP-142 reactive protein. By this 
assay, the highest level of expression of C-HisPfMSP-l42 reached 794.96|ig/ml 
hemolymph from infected silkworms at day six (d.p.i.= 6) after infection. The 
expression level of the two N-HisPfMSP-142 constructs, ivz. 3D7 and FVO, were 
quantified as described in section 3. 5. Interestingly from the time course expression 
result of the N-terminal His tag constructs, the expression level obtained were nearly 
ten-fold lower than that of the C-HisPfMSP-l42 construct. This low expression level 
may have been due to the severe sickness of the silkworm encountered in these 
experiment. We only used low MOI infection in this study because previously our 
laboratory has demonstrated that a MOI= 1 can give a higher expression of the 
recombinant protein in vitro. This enhancing yield was probably due to a delayed 
effect of infection at low MOI, which would otherwise result in rapid killing of insect 
cells due to high concentrations of the virus. 
Compared with a non-histidine tagged construct, which our laboratory has 
prepared previously, the level of expression by C-HisPfMSP-Ui BmNPV was almost 
doubled (794.96^g/ml vs. 450|ig/ml). This might be accountable by the different 
methods used for virus purification. In the ELISA screening method, recombinant 
viruses with the highest expression level in each round were selected. Because of this, 
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clones with optimal homologous recombination yielding the highest level of protein 
expression were picked. 
Since large-scale production of recombinant C-HisPfMSP-Ui protein is our 
final goal, in vitro expression of recombinant protein in cell culture may not be 
economical as the medium used is expensive and yield is low (approximately 7mg/L). 
Moreover, optimization of downstream process, such as that described by Slower (et 
al. 2001)，may also reduce the yield and increase cost significantly. In contrast, the 
natural host of BmNPV, the silkworm larva, is readily available in large quantity in 
eastern and southern China. As the rearing of silkworms is well established and the 
cost is low, it is an attractive alternative to produce recombinant baculovirus proteins 
commercially. Hence, using the silkworm as bioreactor to express C-HisPfMSP-Ui 
protein appears to be a cost-effective way in scaling up the production of a vaccine for 
further clinical trial. 
6. 3 Purification of recombinant C-HisPfMSP-lai protein 
In our laboratory, we have used immunoaffinity chromatography with 
monoclonal antibody mAb5.2 coupled to Sepharose 4B to successfully purified the 
PfMSP-142 protein from BmN infected silkworm hemolymph (Pang 2000). However, 
as the final goal is to make a recombinant vaccine for human clinical trial, purification 
by immunoaffinity chromatography may not satisfy the safety and regulatory 
requirements of government agencies such as the U.S. Food and Drug Administration 
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(FDA). For example, using murine monoclonal antibody for preparation of the 
affinity column, one must demonstrated that no immunoglobulin will leach from the 
matrix during purification (Chang, 1994). In order to avoid the complex issues facing 
immunoaffinity chromatography, we have tried a number of conventional 
chromatographic media in a previous study to purify the PfMSP-142. Unfortunately, 
we were not able to establish an effective purification scheme. Different 
chromatographic media, such as Q-Sepharose Fast Flow, POROS HS/M and ConA 
Sepharose, have been tried and they were only able to produce partial purification of 
the PfMSP-142 protein individually. Unfortunately, when they were combined in an 
attempt to further purify the recombinant protein, they all resulted in either a lack of 
further improvement or the severe loss of the protein of interest. In the present study, 
we have used immobilized metal ion affinity chromatography (IMAC) to isolate the 
recombinant protein. Since the affinity group recognized by this type of 
chromatography is a hexa-histidine sequence, vectors were designed to contain a 
fusion protein of PfMSP-142 with a hexa-histidine tail at either the C- or the 
N-terminal of the Sp42 sequence. The construct with the hexa-histidine C-terminal 
(3D7) has been selected for detailed study. 
Different elution schemes have been evaluated to optimize the purification of 
the C-HisPfMSP-l42 protein in a one step IMAC procedure. These included varying 
pH, salt concentration, imidazole concentration, detergent addition and 
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p-mercaptoethanol addition. After a number of trials, an optimized condition was 
established resulting in 42% purity in a single IMAC (see section 4. 1. 3). The 
combined use of 2M NaCl and step-wise increase of imidazole concentration and 
decrease in pH were probably effective in removing non-specific interacting 
contaminants from the gel matrix. Since washing the column alone by changing pH or 
increasing imidazole concentration were not effective in removing contaminants, we 
rationalize by combining these two schemes together better results might be obtained. 
The use of 0.4M imidazole at pH5.5 was apparently effective in striping out the 
his-tagged protein in the final step. This presumably can concentrate all the protein of 
interest in one or two column volumes. 
In the present purification protocol, a severe loss of recombinant protein was 
observed. The extensive sample manipulation probably contributed to the loss of 
C-HisPfMSP-l42 protein particularly during the dialysis and concentration processes. 
Moreover, the purified C-HisPfMSP-l42 protein appeared to be unstable and 
degradation occurred when dialysis was performed overnight at 4°C. In addition, 
protein precipitation was also observed when the purified sample was concentrated by 
ultrafiltration. Western blot analysis of the precipitated materials revealed the 
presence of a substantial amount of the C-HisPfMSP-Uz protein. Since only the 
soluble material was collected and analyzed, a significant lost of the recombinant 
protein could result in this step. 
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To further purify the recombinant C-HisPfMSP-l42 protein, we evaluated the 
use of conventional chromatography to further purify the materials isolated by IMAC. 
A total of two purification schemes were tested. The first protocol was the use of 
cation-exchange chromatography (POROS HS/M) as a pre-cleaning. Unfortunately, 
no improvement in purity could be obtained and on the contrary, severe loss of the 
C-HisP£MSP-l42 protein was noticed after ion-exchange chromatography. In the 
second protocol, molecular sizing chromatography (Superose 6 in FPLC) was used for 
further purification after IMAC. A highly purified C-HisPfMSP-l42 protein was 
obtained and this step seemed to be particularly effective in removing the high MW 
contaminants (section 4. 3. 2). Unfortunately, the yield of this protocol was low. This 
might have been caused by non-specific absorption during size-exclusion 
chromatography as the sample was highly diluted. Moreover, as we have only 
collected the fractions with the highest purity, some protein of interest might have 
been lost in the overlapping peak fractions. Although highly purified C-HisPfMSP-Ui 
was obtained in this purification scheme, its low yield and low concentration make 
this procedure undesirable. Further work needs to be done to improve the yield and 
optimize conditions for concentrating the recombinant protein so that protein 
precipitation could be avoided. 
6. 4 Characterization of recombinant C-HisPfMSP-lii protein 
In the previous study in our laboratory (Pang 2000), BmNPV-expressed 
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recombinant PfMSP-142 protein has been proven to be biologically and 
immunologically active. By a competitive inhibition ELISA, the recombinant 
PfMSP-142 protein was shown to behave similarly as the native PfMSP-1 protein. The 
recombinant protein was also highly immunogenic and was able to induce extremely 
high anti-PfMSP-l42 titers. Most importantly, the antisera raised against PfMSP-142 
was demonstrated to be effective in inhibiting parasite proliferation in an in vitro 
experiment. Taken together, these results strongly suggest the effectiveness of the 
recombinant PMSP-I42 protein as an anti-erythrocytic malaria vaccine candidate. 
In the present study, preliminary immunoassays were performed to investigate 
the conformation and immunogenicity of the hexa-histidine tailed PfMSP-142 protein. 
The reduction sensitive disulphide-dependent conformational epitopes in the 
recombinant C-HisPfMSP-Ui was determined in a protein reduction experiment. As 
the monoclonal antibody, mAb5.2, specifically recognizes the disulphide-dependent 
conformation epitope on the carboxyl-terminal of the native PfMSP-1 protein, it was 
used to exam the integrity of the C-terminal conformation. Under non-reducing 
(native) condition, mAb5.2 reacted with C-HisPfMSP-142 protein strongly (Figure 44, 
lane 0). In contrast, such reactivity was significantly reduced when the protein was 
treated with increasing concentration of P-mercaptoethanol. This result agrees with 
previous findings (Chang et al, 1992; Locher & Tarn, 1993) that the 
disulphide-dependent conformation is essential to the antigenicity of the PMSP-I42 
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protein. The sensitivity of our recombinant protein to reduction indicates that the 
BmNPV-expression system has produced a correctly folded C-HisPfMSP-Ui. 
The antigenicity of the C-HisPfMSP-l42 protein was examined in a mouse 
immunization experiment as described in section 2. 2. 10. The antibody titer obtained 
was low compared with the immunization results using the unmodified PfMSP-142. 
(End-point titers >1/4,000,000). This might have been due to different amounts of 
antigen used, the number of boosters applied as well as mice instead of rabbits being 
used. In the previous study, after the 1st immunization, three additional boosters were 
injected. But in the present study, a total of three immunizations were applied and the 
first one did not elicit any antibody titer. Only after the first booster with IFA, we 
were able to observe any antibody titer. This may have been the reason why a low 
titer was observed. As the immunization schedule in the present experiment was not 
kept properly, fiirther experiments are needed to evaluate if C-HisPfMSP-Ui has 
similar immunogenicity as the unmodified protein. 
In sum, the BmNPV expressed recombinant C-HisPfMSP-Ui protein 
produced in the present study has been demonstrated to be conformationally similar to 
native PfMSP-1 and immunologically active. Moreover, this recombinant protein has 
an advantage over the unmodified one because it has a hexa-histidine tail which can 
facilitate its purification by IMAC. The high level expression of recombinant protein 
in silkworm and its low operating cost in production and purification make the 
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technique attractive in the scale up production of C-HisPfMSP-Ui for vaccination 
studies. 
6. 5 Future Prospects 
The one step IMAC scheme used in the present study was only partly 
successful in purifying the recombinant C-HisPfMSP-Ui. The disulphide-dependent 
conformation at the C-terminal of the recombinant protein may have some influence 
on the accessibility of the hexa-his residues (section 5.2). Thus, the interaction 
between the Ni charged group in the column matrix and the hexa-histidine residues 
might be restricted by this conformational effect. To resolve this problem, we have 
tried to purify C-HisPfMSP-l42 in IMAC with low concentration of 
P-mercaptoethanol (5mM) supplemented in the elution buffer. Preliminary result 
showed that an enrichment in purity could be obtained. On the other hand, placing the 
hexa-histidine tail at the N-terminal may overcome this problem as no disulphide 
domains are on this side of the protein. The N-terminal constructs have been made 
and expressed successfully in BmNPV-infected silkworm expression system. We 
hope that this recombinant protein can be efficiently purified by IMAC with higher 
recovery. However, it is important to point out that in the production of vaccines, the 
yield of the purification process should not be the major deciding factor. Two other 
factors are equally important: the expression level and the potency of the purified 
vaccine. If the expression level is very high (average recombinant C-HisPfMSP-Ui 
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protein expressed = 450ng/^il hemolymph) and the potency (further studies are needed 
to clarify the immunogenicity of the recombinant protein) of the vaccine is excellent, 
then the yield of the purification protocol can be low and still remains a viable option. 
Expression level of recombinant C-HisPfMSP-Ui protein can be further 
enhanced by optimizing the use of the polh promoter. Maeda (1994) has noticed that 
the expression level of a foreign gene under the controlled of polh promoter could 
drop to only 0.1-10% of that of the original polyhedrin gene. In the future, transfer 
vectors carrying different length of sequences between the polh promoter and the 
structural gene can be designed to investigate the optimal spacing to improve 
expression level of the recombinant protein. 
In this study, one of the major obstacles to establish a practical large scale 
recombinant protein production and purification scheme is the variation in yield 
caused by optimization of time to harvest infected silkworms from batch to batch. 
Thus, if infected silkworms were not harvested in time, over-infection may result and 
the larva will die resulting in melanization of the hemolymph. Under such condition, 
proteins and lipids, including the product of interest, will turn into a dark black gluey 
gum which makes recovery impossible. Therefore, the success of the silkworm 
expression system not just hinges on synchronizing infection but also synchronizing 
the harvesting. Green Fluorescent Protein (GFP; specifically a UV variant, GFPuv) 
(Crameri et al.’ 1996) could be used as an effective indicator of product level (Cha et 
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al.，1997) in baculovirus expression. For example, side-by-side expression of 
recombinant BmNPV carrying the C-HisPfMSP-Uz gene and the GFP sequence could 
be used to overcome the timing process. The expression of GFP could be monitored 
continuously to optimize the best time for harvest (see Figure 47). 
In order to further investigate the conformational similarity between the 
recombinant protein and the native MSP-1, competitive binding ELISA assays using 
MSP-119 or MSP-142 (non-histidine tagged) as comparisons can be performed other 
than reduction-sensitive (disulphide-dependent conformation) test. 
The main objective of our research is to establish a reproducible scale-up 
process for making sufficient amount of C-HisPfMSP-l42 antigen to carry out monkey 
and human trial for malaria protection. In order to do this, we have to further confirm 
the biological and immunological activity of the recombinant his-tagged protein. 
Based on previous studies using similar immunogens (Chang et al., 1992; 1996; Hui 
et al.，1993), we are confident that the BmNPV-expressed recombinant 
C-HisPfMSP-l42 protein can be used as an anti-malaria vaccine in limiting the blood 
stage parasite proliferation. 
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Figure 47. Side-by-side expression construct of recombinant baculovirus. (A) Green 
fluorescent baculovirus-infected insect T. ni larvae. From the top to bottom: 24,48, 60， 
74, and 84 hpi (hours post infection) larvae samples. Larvae were photographed under 
irradiation of long-wave (365 nm) UV light (transilluminator box held over top of 
samples). (B) Time course of larvae mass, GFPuv fluorescence intensity, and hIL-2 
(interleukin-2 was used as model product in this experiment) mass in 
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Biomark 2000 (Beckman) program for sandwich ELISA protocol 
S e t u p Conf igurat ion 
T o o l R a c k at A 2 
Manna丨 M o v e 96 -we l l f lat to 1 C 8 
M a n u a l M o v e 96 -we l l flat to 1 C 7 
M a n u a l M o v e 96-wel l fiat to 1 C 6 
M a n u a l M o v e 96-wel l f lat to 1 C 5 
M a n u a l M o v e 96 -we l l f lat to 1 C 4 
M a n u a l M o v e 96-wel l fiat to A 4 
M a n u a l M o v e 96 -we l l f lat to A 5 
M a n u a l M o v e 96 -we l l f iat to A 6 
M a n u a l M o v e 96 -we l l f lat to B5 
M a n u a l M o v e 96 -we l l flat to B6 
M a n u a l M o v e P 2 5 0 T i p Holder to B 2 
M a n u a l M o v e Full Reservo i r 1 5 0 m l " P B S . B S A " to B 3 
M a n u a l M o v e 96 -we l l flat "pre-wash plate" to A 3 
M a n u a l M o v e Full Reservo i r to B1 
Initial Conf igurat ion 
Bulk D ispense 5 . 0 0 0 ml Port 1 to B1 using W a s h 8 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 3 using W a s h 8 
Aspirate A 3 for 1 . 0 0 second using W a s h S 
Begin Loop: Count = 3 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 3 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 4 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 6 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to B5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to B6 using W a s h S 
Aspira te A 3 for 2 . 0 0 seconds using W a s h S 
Aspirate A 4 for 2 . 0 0 seconds using W a s h S 
Aspira te A 5 for 2 . 0 0 seconds using W a s h S 
Aspirate A 6 for 2 . 0 0 seconds using W a s h S 
Aspira te B 5 for 2 . 0 0 seconds using W a s h S 
Aspirate B6 for 2 . 0 0 seconds using W a s h S 
E n d Loop ( m a n u a l P B S . B S A addit ion 2 0 0 m l ) 
P ipet te 2 0 0 . 0 0 pi f r o m 8 3 to A 4 using M P 2 0 0 - P 2 5 0 
Pipet te 2 0 0 . 0 0 pi f rom B 3 to A 5 using M P 2 0 0 - P 2 5 0 
Pipet te 2 0 0 . 0 0 pi f rom B 3 to A 6 using M P 2 0 0 - P 2 5 0 
Pipet te 2 0 0 . 0 0 pi f rom B 3 to B5 using M P 2 0 0 - P 2 5 0 
Pipet te 2 0 0 . 0 0 pi f rom B 3 to B6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -wel l flat to 1 B 8 
A u t o m a t i c M o v e A 5 , 96 -we l l fiat to 1 B 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 B 6 
A u t o m a t i c M o v e B5 , 96 -we l l f lat to 1 B 5 
A u t o m a t i c M o v e B6 , 96 -we l l f lat to 1 B 4 
A u t o m a t i c M o v e 1 C 8 , 96 -we l l flat to A 4 
A u t o m a t i c M o v e 1 C 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 C 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 C 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 C 4 , 96 -we l l flat to B6 
Beg in Loop: C o u n t = 3 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 4 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 6 using W a s h S 
Aspi ra te A 3 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d Loop 
P ipet te 2 0 0 . 0 0 pi f r o m B 3 to A 4 using M P 2 0 0 - P 2 5 0 
P ipet te 2 0 0 . 0 0 pi f r o m B 3 to A 5 using M P 2 0 0 - P 2 5 0 
P ipet te 2 0 0 . 0 0 pi f r o m B 3 to A 6 using M P 2 0 0 - P 2 5 0 
P ipet te 2 0 0 . 0 0 pi f r o m B 3 to 8 5 using M P 2 0 0 - P 2 5 0 
P ipet te 2 0 0 . 0 0 pi f r o m B 3 to B 6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 1 C 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 1 C 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 C 6 
A u t o m a t i c M o v e B5 , 96 -we l l f lat to 1 C 5 
A u t o m a t i c M o v e B6 , 96 -we l l f lat to 1 C 4 
A u t o m a t i c M o v e 1 B 8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 B 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 B 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 B 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 B 4 , 96 -we l l f iat to B 6 
S y s t e m : P a u s e for = 0 0 : 2 3 : 0 0 , M e s s a g e 
Asp i ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te R 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
Bulk D ispense 1 0 . 0 0 0 ml Port 2 to B 3 using W a s h S 
Beg in Loop: C o u n t = 3 
Bulk D ispense 0 . 2 0 0 m l Port 2 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to A S using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 2 . 0 0 seconds using W a s h S 
Asp i ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 s e c o n d s using W a s h S 
E n d Loop 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 1 B 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 1 B 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 B 6 
A u t o m a t i c M o v e B 5 , 96 -we l l f lat to 1 B 5 
A u t o m a t i c M o v e B 6 , 96 -we l l f lat to 1 B 4 (first round of cul ture m e d i u m s a m p l e addi t ion) 
A u t o m a t i c M o v e 1 C 8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 C 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 C 6 , 9 6 - w e l l f lat to A 6 
A u t o m a t i c M o v e 1 C 5 , 9 6 - w e l l f lat to B 5 
A u t o m a t i c M o v e 1 C 4 , 9 6 - w e l l f lat to B 6 
S y s t e m : P a u s e for = 0 0 : 0 3 : 0 0 , M e s s a g e 
Asp i ra te A 4 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 6 for 2 . 0 0 s e c o n d s using W a s h S 
Beg in Loop: C o u n t = 3 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 3 using W a s h 8 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to B 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d Loop 
E N D 
S e t u p Conf igurat ion 
T o o l R a c k at A 2 
M a n u a l M o v e P 2 5 0 T i p Ho lder to B 2 
M a n u a l M o v e Full R e s e r v o i r "An t i -SP42 /Subs" to B 3 
M a n u a l M o v e 96 -we l l f lat "pre-wash" to A 3 
M a n u a l M o v e 96 -we l l f lat to A 4 
M a n u a l M o v e 96 -we l l f iat to A 5 
M a n u a l M o v e 96 -we l l f lat to A 6 
M a n u a l M o v e 9 6 - w e l l f lat to B 5 
M a n u a l M o v e 96 -we l l f lat to B 6 
M a n u a l M o v e 9 6 - w e l l f lat to 1 C 8 
M a n u a l M o v e 86 -we l l f lat to 1 C 7 
M a n u a l M o v e 9 6 - w e l l f lat to 1 C 6 
M a n u a l M o v e 96 -we l l f lat to 1 C 5 
M a n u a l M o v e 96 -we l l f lat to 1 C 4 
M a n u a l M o v e Ful l Reservo i r " H R P conjugate" to B 4 
M a n u a l M o v e Full R e s e r v o i r "water" to B1 
Initial Conf igurat ion ( R e m o v e s a m p l e solution of first 5 p la tes m a n u a l l y ) 
Asp i ra te B1 for 2 0 . 0 0 seconds using W a s h S 
Beg in Loop: C o u n t = 3 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Asp i ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Asp i ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 6 fa r 2 . 0 0 s e c o n d s using W a s h S 
E n d L o o p 
S y s t e m : P a u s e until cance l led . M e s s a g e . A l a r m (First round of A n t i - S p 4 2 A b addi t ion) 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 4 using M P 2 0 0 - P 2 5 0 
P ipe t te 1 0 0 . 0 0 pi f r o m B 3 to A 5 using M P 2 0 0 - P 2 5 0 
P ipe t te 1 0 0 . 0 0 pi f r o m B 3 to A 6 using M P 2 0 0 - P 2 5 0 
P ipe t te 1 0 0 . 0 0 pi f r o m B 3 to B 5 using M P 2 0 0 - P 2 5 0 
P ipe t te 1 0 0 . 0 0 pi f r o m B 3 to B 6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 9 6 - w e l l f lat to 1 B 8 
A u t o m a t i c M o v e A 5 , 9 6 - w e l l f lat to 1 B 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 B 6 
A u t o m a t i c M o v e B 5 , 9 6 - w e l l f lat to 1 B 5 
A u t o m a t i c M o v e B 6 , 9 6 - w e l l f lat to 1 B 4 
A u t o m a t i c M o v e 1 C 8 , 9 6 - w e l l f lat to A 4 
A u t o m a t i c M o v e 1 C 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 C 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 C 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 C 4 , 96 -we l l f lat to B 6 
Beg in Loop: C o u n t = 3 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 3 using W a s h S 
Bulk D ispense 0 . 2 0 0 m l Port 2 to A 4 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d Loop 
S y s t e m : P a u s e until cance l led , M e s s a g e , A l a r m ( S e c o n d round of A n t i - S p 4 2 A b 
addit ion) 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 4 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 6 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to B 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 0 0 ill f r o m B 3 to B 6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l flat to 1 C 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 1 C 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 C 6 
A u t o m a t i c M o v e B5 , 96 -we l l f lat to 1 C 5 
A u t o m a t i c M o v e B 6 , 96 -we l l f lat to 1 C 4 
A u t o m a t i c M o v e 1 B 8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 B 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 B 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 B5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 B 4 , 96 -we l l f lat to B 6 
Bulk D i s p e n s e 1 0 . 0 0 0 m l Port 1 to B 3 using W a s h S 
S y s t e m : P a u s e for = 0 0 : 1 9 : 0 0 , M e s s a g e 
Asp i ra te B1 for 2 0 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
B e g i n Loop: C o u n t = 5 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 6 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 6 for 2 . 0 0 s e c o n d s using W a s h S 
E n d L o o p 
S y s t e m : P a u s e until cance l led , M e s s a g e . A l a r m (First round of H R P - c o n j u g a t e A b 
addi t ion) 
P ipe t te 1 0 0 . 0 0 pi f r o m B 4 to A 4 using M P 2 0 0 - P 2 5 0 
I 
Pipet te 1 0 0 . 0 0 pi f r o m B4 to A 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to A 6 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f rom B 4 to B 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to B6 using M P 2 0 0 • P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 1 B 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 1 B 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 B 6 
A u t o m a t i c M o v e B5 , 96 -we l l f lat to 1 B 5 
A u t o m a t i c M o v e B6 , 96 -we l l flat to 1 B 4 
A u t o m a t i c M o v e 1 C 8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 C 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 C 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 C 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 C 4 , 96 -we l l f lat to B 6 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
Beg in Loop: C o u n t = 5 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to 8 6 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d Loop ( S e c o n d round of H R P - c o n j u g a t e d Abaddi t ion) 
S y s t e m : P a u s e until cance l led . M a s s a g e , A l a r m 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to A 4 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to A 5 using M P 2 0 0 • P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to A 6 using M P 2 0 0 • P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 4 to B 5 using M P 2 0 0 • P 2 5 0 
P ipet te 1 0 0 0 0 hi f r o m B 4 to B 6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 1 C 8 
A u t o m a t i c M o v e AS, 96 -we l l f lat to 1 C 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 C 6 
A u t o m a t i c M o v e B 5 , 96 -we l l f lat to 1 C 5 
A u t o m a t i c M o v e B 6 , 9 6 - w e l l f lat to 1 C 4 
A u t o m a t i c M o v e 1 B 8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 B 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 B 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 B 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 B 4 , 9 6 - w e l l f lat to B 6 
Asp i ra te A 4 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 6 for 2 . 0 0 seconds using W a s h S 
Asp i ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 6 for 2 . 0 0 s e c o n d s using W a s h S 
B e g i n Loop: C o u n t = 3 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Por t 1 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Por t 1 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to B 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 1 to B 6 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d loop 
Bulk D i s p e n s e 1 0 . 0 0 0 ml Port 2 to B 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 2 to B 6 using W a s h S 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 1 B 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 1 B 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 1 B 6 
A u t o m a t i c M o v e B 5 , 96 -we l l f lat to 1 B 5 
A u t o m a t i c M o v e B6 , 96 -we l l f iat to 1 B 4 
A u t o m a t i c M o v e 1 C 8 , 96 -we l l f lat to A d 
A u t o m a t i c M o v e 1 C 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 C 6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 C 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 C 4 , 96 -we l l f lat to B 6 
Bulk D i s p e n s e 1 0 . 0 0 0 m l Port 1 to B 3 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 6 for 2 . 0 0 seconds using W a s h S 
Beg in Loop: C o u n t = 3 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 3 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 1 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 5 using W a s h 8 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to A 6 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to B 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 m l Port 1 to B 6 using W a s h S 
Asp i ra te A 3 for 1 . 0 0 s e c o n d using W a s h S 
Asp i ra te A 4 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te A 6 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 5 for 2 . 0 0 s e c o n d s using W a s h S 
Asp i ra te B 6 for 2 . 0 0 s e c o n d s using W a s h S 
E n d L o o p 
Bulk D i s p e n s e 1 0 . 0 0 0 m l Port 2 to B 3 using W a s h S 
Beg in Loop: C o u n t = 2 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 3 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to A 4 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 5 using W a s h S 
Bulk D i s p e n s e 0 . 2 0 0 ml Port 2 to A 6 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to B 5 using W a s h S 
Bulk D ispense 0 . 2 0 0 ml Port 2 to B 6 using W a s h S 
Aspi ra te A 3 for 1 . 0 0 second using W a s h S 
Aspi ra te A 4 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
E n d Loop 
S y s t e m : P a u s e until cance l led , M e s s a g e , A l a r m 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 4 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B3 to A 6 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to B5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m to B6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 2 A 8 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 2 A 7 
A u t o m a t i c M o v e A 6 , 96 -we l l f lat to 2 A 6 
A u t o m a t i c M o v e B 5 , 96 -we l l f lat to 2 A 5 
A u t o m a t i c M o v e B 6 , 96 -we l l f lat to 2 A 4 
A u t o m a t i c M o v e 1 B8 , 96 -we l l f lat to A 4 
A u t o m a t i c M o v e 1 B 7 , 96 -we l l f lat to A 5 
A u t o m a t i c M o v e 1 B6 , 96 -we l l f lat to A 6 
A u t o m a t i c M o v e 1 B 5 , 96 -we l l f lat to B 5 
A u t o m a t i c M o v e 1 B 4 , 96 -we l l f lat to B 6 
Asp i ra te A 4 for 2 . 0 0 s e c o n d s using W a s h S 
Aspi ra te A 5 for 2 . 0 0 seconds using W a s h S 
Asp i ra te A 6 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 5 for 2 . 0 0 seconds using W a s h S 
Aspi ra te B 6 for 2 . 0 0 seconds using W a s h S 
S y s t e m : P a u s e until cance l led , M e s s a g e , A l a r m 
P ipe t te 1 0 0 . 0 0 pi f r o m B 3 to A 4 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 5 using M P 2 0 0 • P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to A 6 using M P 2 0 0 - P 2 5 0 
P ipe t te 1 0 0 . 0 0 pi from B 3 to B 5 using M P 2 0 0 - P 2 5 0 
P ipet te 1 0 0 . 0 0 pi f r o m B 3 to B6 using M P 2 0 0 - P 2 5 0 
A u t o m a t i c M o v e A 4 , 96 -we l l f lat to 2 A 3 
A u t o m a t i c M o v e A 5 , 96 -we l l f lat to 2 A 2 
A u t o m a t i c M o v e A 6 . 96 -we l l f lat to 2 A 1 
A u t o m a t i c M o v e B 5 , 96 -we l l f lat to 2 F 4 
A u t o m a t i c M o v e B6 . 96 -we l l f lat to 2 F 3 
A u t o m a t i c M o v e 2 A 8 , 9 6 - w e l l f lat to 1 F 1 
E x e c u t e P l a t e R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 B 8 
A u t o m a t i c M o v e 2 A 7 , 96 -we l l f lat to 1 F 
E x e c u t e P l a t e R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 B 7 
A u t o m a t i c M o v e 2 A 6 , 96 -we l l f lat to 1 F 1 
E x e c u t e P l a t e R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 9 6 - w e l l f lat to 1 B 6 
A u t o m a t i c M o v e 2 A 5 , 9 6 - w e l l f lat to 1 F 1 
E x e c u t e P l a t e R e a d e r Protocol : C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F , 9 6 - w e l l f lat to 1 B 5 
A u t o m a t i c M o v e 2 A 4 , 9 6 - w e l l f lat to 1 F 1 
E x e c u t e P l a t e R e a d e r Protocol : C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 9 6 - w e l l f lat to 1 B 4 
S y s t e m : P a u s e for = 0 0 : 0 4 : 0 0 , M e s s a g e 
A u t o m a t i c M o v e 2 A 3 , 96 -we l l f lat to 1 F 1 
E x e c u t e P la te R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 C 8 
A u t o m a t i c M o v e 2 A 2 , 96 -we l l f lat to 1 F 1 
E x e c u t e P la te R e a d e r Protocol: C : I S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 C 7 
A u t o m a t i c M o v e 2 A 1 , 96 -we l l f lat to 1 F 
E x e c u t e P la te R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 C 6 
A u t o m a t i c M o v e 2 F 4 , 96 -we l l flat to 1 F 1 
E x e c u t e P la te R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 C 5 
A u t o m a t i c M o v e 2 F 3 , 96 -we l l f lat to 1 F 1 
E x e c u t e P la te R e a d e r Protocol: C : \ S O F T M A X \ s h a n . p r o 
A u t o m a t i c M o v e 1 F 1 , 96 -we l l f lat to 1 C 4 
E N D 
APPENDIX 3 
Nucleotide Sequence of PfMSP-l』，3D7 Isolate 
atggcaa tatctgtcac aatggataat atcctctcag gatttgaaaa tgaatatgat 
gttatatatt taaaaccttt agctggagta tatagaagct taaaaaaaca aattgaaaaa 
aacattttta catttaattt aaatttgaac gatatcttaa attcacgtct taagaaacga 
aaatatttct tagatgtatt agaatctgat ttaatgcaat ttaaacatat atcctcaaat 
gaatacatta ttgaagattc atttaaatta ttgaattcag aacaaaaaaa cacactttta 
aaaagttaca aatatataaa agaatcagta gaaaatgata ttaaatttgc acaggaaggt 
ataagttatt atgaaaaggt tttagcgaaa tataaggatg atttagaatc aattaaaaaa 
gttatcaaag aagaaaagga gaagttccca tcatcaccac caacaacacc tccgtcacca 
gcaaaaacag acgaacaaaa gaaggaaagt aagttccttc catttttaac aaacattgag 
accttataca ataacttagt taataaaatt gacgattact taattaactt aaaggcaaag 
attaacgatt gtaatgttga aaaagatgaa gcacatgtta aaataactaa acttagtgat 
ttaaaagcaa ttgatgacaa aatagatctt tttaaaaacc cttacgactt cgaagcaatt 
aaaaaattga taaatgatga tacgaaaaaa gatatgcttg gcaaattact tagtacagga 
ttagttcaaa attttcctaa tacaataata tcaaaattaa ttgaaggaaa attccaagat 
atgttaaaca tttcacaaca ccaatgcgta aaaaaacaat gtccagaaaa ttctggatgt 
ttcagacatt tagatgaaag agaagaatgt aaatgtttat taaattacaa acaagaaggt 
gataaatgtg ttgaaaatcc aaatcctact tgtaacgaaa ataatggtgg atgtgatgca 
gatgccacat gtaccgaaga agattcaggt agcagcagaa agaaaatcac atgtgaatgt 
actaaacctg attcttatcc acttttcgat ggtattttct gcagttcctaa 
The complete sequence of PfMSP-1 can be found in GenBank (NCBI) under the 
accession number Z35327. The start and stop codons are blot (atg and taa). 
Amino Acid Sequence of PfMSP-ld^ 
MAISVTMDNI LSGFENEYDV lYLKPLAGVY RSLKKQIEKN IFTFNLNLND ILNSRLKKRK 
YFLDVLESDL MQFKHISSNE YIIEDSFKLL NSEQKNTLLK SYKYIKESVE NDIKFAQEGI 
SYYEKVLAKY KDDLESIKKV IKEEKEKFPS SPPTTPPSPA KTDEQKKESK FLPFLTNIET 
LYNNLVNKID DYLINLKAKI NDCNVEKD冠 HVKITKLSDL KAIDDKIDLF KNPYDFEAIK 
KLINDDTKKD MLGKLLSTGL VQNFPNTIIS KLIEGKFQDM LNISQHQCVK KQCPENSGCF 
RHLDEREECK CLLNYKQEGD KCVENPNPTC NENNGGCDAD ATCTEEDSGS SRKKITCECT 
KPDSYPLFDG IFCSS* 
The start and stop codons are indicated as M and * respectively. Positions of cysteine 
residues are marked as C. Potential N-linked (NXS/NXT; X: all except P and D) and 
0-linked (P/S/T-rich regions) glycosylation sites are underlined. 
APPENDIX 4 
Nucleotide sequence of PfMSP-lji FVO isolate 
1 gcagtaactc cttccgtaat tgataacata ctttctaaaa ttgaaaatga atatgaggtt 
61 ttatatttaa aacctttagc aggtgtttat agaagtttaa aaaaacaatt agaaaataac 
121 gttatgacat ttaatgttaa tgttaaggat attttaaatt cacgatttaa taaacgtgaa 
181 aatttcaaaa atgttttaga atcagattta attccatata aagatttaac atcaagtaat 
241 tatgttgtca aagatccata taaatttctt aataaagaaa aaagagataa attcttaagc 
301 agttataatt atattaagga ttcaatagat acggatataa attttgcaaa tgatgttctt 
361 ggatattata aaatattatc cgaaaaatat aaatcagatt tagattcaat taaaaaatat 
421 atcaacgaca aacaaggtga aaatgagaaa taccttccct ttttaaacaa tattgagacc 
481 ttatataaaa cagttaatga taaaattgat ttatttgtaa ttcatttaga agcaaaagtt 
541 ctaaattata catatgagaa atcaaacgta gaagttaaaa taaaagaact taattactta 
601 aaaacaattc aagacaaatt ggcagatttt aaaaaaaata acaatttcgt tggaattgct 
661 gatttatcaa cagattataa ccataataac ttattgacaa agttccttag tacaggtatg 
721 gtttttgaaa atcttgctaa aaccgtttta tctaatttac ttgatggaaa cttgcaaggt 
781 atgttaaaca tttcacaaca ccaatgcgta aaaaaacaat gtccacaaaa ttctggatgt 
841 ttcagacatt tagatgaaag agaagaatgt aaatgtttat taaattacaa acaagaaggt 
901 gataaatgtg ttgaaaatcc aaatcctact tgtaacgaaa ataatggtgg atgtgatgca 
961 gatgccaaat gtaccgaaga agattcaggt agcaacggaa agaaaatcac atgtgaatgt 
1021 actaaacctg attcttatcc acttttcgat ggtattttct gcagttcctc taa 
This Plasmodium falciparum Vetnam Oak knoll (FVO) strain sequence was came 
from GeneBlank(NCBI) under the assession number GI:309745. 
APPENDIX 5 
Efficiency of the mAb5.2 immunoaffinity column in purifying the recombinant 
PfMSP-ld, protein. 
Trial N o . T o t a l PfMSP-142 protein Yield of PfMSP-Ui % Recovery 
loaded (^ig)* protein in eluted 
fractions^ 
1 s t 508.8 188.0 37^ 
2nd 793.6 341.1 43.0 
* as determined by sandwich ELISA. 
# total yield from the first two eluted fractions. 
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